

Giuseppe Boriani,, Fehra, Fesc

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7094935/publications.pdf>

Version: 2024-02-01

719
papers

40,328
citations

5268

83
h-index

4015

176
g-index

745
all docs

745
docs citations

745
times ranked

23704
citing authors

#	ARTICLE	IF	CITATIONS
1	Withdrawn as duplicate: Optimized Implementation of cardiac resynchronization therapy â€“ a call for action for referral and optimization of care. <i>Europace</i> , 2023, 25, .	1.7	2
2	Impact of body mass index on the outcome of elderly patients treated with transcatheter aortic valve implantation. <i>Internal and Emergency Medicine</i> , 2022, 17, 369-376.	2.0	6
3	Screening for Atrial Fibrillation in Relation to Stroke and Mortality Risk. <i>Thrombosis and Haemostasis</i> , 2022, 122, 171-175.	3.4	9
4	Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 70-84.	3.3	25
5	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>Europace</i> , 2022, 24, 71-164.	1.7	370
6	European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology. <i>Europace</i> , 2022, 24, 165-172.	1.7	20
7	Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General Registry. <i>Europace</i> , 2022, 24, 202-210.	1.7	9
8	Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 778-786.	4.0	15
9	Burden of disease and costs of infections associated with cardiac implantable electronic devices. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 7-16.	1.4	4
10	Implantation of cardiac electronic devices in active COVID-19 patients: Results from an international survey. <i>Heart Rhythm</i> , 2022, 19, 206-216.	0.7	12
11	Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry. <i>Europace</i> , 2022, 24, 721-728.	1.7	12
12	Atrial fibrillation ablation in heart failure: Findings from the ESC-EHRA EORP Atrial Fibrillation Ablation long-term (AFA LT) registry. <i>International Journal of Cardiology</i> , 2022, 346, 19-26.	1.7	2
13	Rhythm- or rate-control strategies according to 4S-AF characterization scheme and long-term outcomes in atrial fibrillation patients: the FAMo (Fibrillazione Atriale in Modena) cohort. <i>Internal and Emergency Medicine</i> , 2022, 17, 1001-1012.	2.0	15
14	Clinical implications of assessing frailty in elderly patients treated with permanent cardiac pacing. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 87-90.	1.5	3
15	Preoperative checklist to reduce the risk of cardiac implantable electronic device infections. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2022, 45, 262-269.	1.2	3
16	Impact of COVID-19 in emergency medicine literature: a bibliometric analysis. <i>Internal and Emergency Medicine</i> , 2022, 17, 1229-1233.	2.0	6
17	Impact of renal impairment on atrial fibrillation: ESCâ€™EHRA EORPâ€™AF Longâ€™Term General Registry. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13745.	3.4	10
18	Incidence and Predictors of Infections and All-Cause Death in Patients with Cardiac Implantable Electronic Devices: The Italian Nationwide RI-AIAC Registry. <i>Journal of Personalized Medicine</i> , 2022, 12, 91.	2.5	14

#	ARTICLE	IF	CITATIONS
19	Atrial high rate episodes as a marker of atrial cardiomyopathy: In the quest of the Holy Grail. Author's reply. <i>European Journal of Internal Medicine</i> , 2022, 98, 115-116.	2.2	4
20	Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration. <i>Circulation</i> , 2022, 145, 392-409.	1.6	65
21	Kidney Function According to Different Equations in Patients Admitted to a Cardiology Unit and Impact on Outcome. <i>Journal of Clinical Medicine</i> , 2022, 11, 891.	2.4	5
22	Vascular Accesses in Cardiac Stimulation and Electrophysiology: An Italian Survey Promoted by AIAC (Italian Association of Arrhythmias and Cardiac Pacing). <i>Biology</i> , 2022, 11, 265.	2.8	2
23	Implantable cardioverter defibrillators and devices for cardiac resynchronization therapy: what perspective for patients's™ apps combined with remote monitoring?. <i>Expert Review of Medical Devices</i> , 2022, 19, 155-160.	2.8	12
24	Performance-based risk-sharing arrangements for devices and procedures in cardiac electrophysiology: an innovative perspective. <i>Europace</i> , 2022, 24, 1541-1547.	1.7	11
25	Ten-year follow-up of cardiac resynchronization therapy patients with non-ischemic dilated cardiomyopathy assessed by radionuclide angiography: a single-center cohort study. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, , .	1.3	0
26	Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry. <i>European Journal of Internal Medicine</i> , 2022, 99, 45-56.	2.2	5
27	Pulmonary arterial hypertension and right ventricular systolic dysfunction in COVID-19 survivors. <i>Cardiology Journal</i> , 2022, 29, 163-165.	1.2	9
28	Atrial High-Rate Episodes Detected by Cardiac Implantable Electronic Devices: Dynamic Changes in Episodes and Predictors of Incident Atrial Fibrillation. <i>Biology</i> , 2022, 11, 443.	2.8	10
29	Case Report: Free-Floating Intracoronary Thrombus: Who Is the Convict?. <i>Frontiers in Oncology</i> , 2022, 12, 825711.	2.8	1
30	Clinical Profile, Arrhythmias, and Adverse Cardiac Outcomes in Emery's Dreifuss Muscular Dystrophies: A Systematic Review of the Literature. <i>Biology</i> , 2022, 11, 530.	2.8	2
31	Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 560-573.	3.3	15
32	Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13773.	3.4	6
33	Arrhythmias in COVID-19/SARS-CoV-2 Pneumonia Infection: Prevalence and Implication for Outcomes. <i>Journal of Clinical Medicine</i> , 2022, 11, 1463.	2.4	6
34	AIM-AF: A Physician Survey in the United States and Europe. <i>Journal of the American Heart Association</i> , 2022, 11, e023838.	3.7	10
35	How to use digital devices to detect and manage arrhythmias: an EHRA practical guide. <i>Europace</i> , 2022, 24, 979-1005.	1.7	107
36	Add-on Therapy With Sacubitril/Valsartan and Clinical Outcomes in CRT-D Nonresponder Patients. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 79, 472-478.	1.9	4

#	ARTICLE	IF	CITATIONS
37	The value of wearable cardioverter defibrillator in adult patients with recent myocardial infarction: Economic and clinical implications from a health technology assessment perspective. International Journal of Cardiology, 2022, 356, 12-18.	1.7	6
38	Mobile health technology in atrial fibrillation. Expert Review of Medical Devices, 2022, 19, 327-340.	2.8	19
39	Chronic Kidney Disease with Mild and Mild to Moderate Reduction in Renal Function and Long-Term Recurrences of Atrial Fibrillation after Pulmonary Vein Cryoballoon Ablation. Journal of Cardiovascular Development and Disease, 2022, 9, 126.	1.6	2
40	Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. European Heart Journal, 2022, 43, 2442-2460.	2.2	43
41	Association between implantable defibrillator-detected sleep apnea and atrial fibrillation: the DASAP-HF study. Journal of Cardiovascular Electrophysiology, 2022, , .	1.7	2
42	Dronedronone for the treatment of atrial fibrillation with concomitant heart failure and preserved or mildly reduced ejection fraction: closer to Ithaca after a long odyssey?. European Journal of Heart Failure, 2022, 24, 1102-1105.	7.1	4
43	Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis from the ESC-EHRA EORP-AF Long-Term General Registry. European Journal of Internal Medicine, 2022, 103, 41-49.	2.2	5
44	Comparing atrial fibrillation guidelines: Focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations. European Journal of Internal Medicine, 2022, 101, 1-7.	2.2	27
45	The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: insights from an individual patient data meta-analysis of COMPANION and CARE-HF. European Journal of Heart Failure, 2022, 24, 1091-1093.	7.1	1
46	The search for a gold standard to clinically diagnose and monitor atrial cardiomyopathy. European Journal of Internal Medicine, 2022, 101, 34-36.	2.2	5
47	Frailty prevalence and impact on outcomes in patients with atrial fibrillation: A systematic review and meta-analysis of 1,187,000 patients. Ageing Research Reviews, 2022, 79, 101652.	10.9	48
48	Atrial cardiomyopathy: a derangement in atrial volumes, geometry, function, and pathology with important clinical implications. Journal of Cardiovascular Medicine, 2022, 23, 359-362.	1.5	12
49	Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: what are the barriers to implementation in the "real world"? European Journal of Heart Failure, 2022, 24, 1223-1226.	7.1	0
50	Feasible approaches and implementation challenges to atrial fibrillation screening: a qualitative study of stakeholder views in 11 European countries. BMJ Open, 2022, 12, e059156.	1.9	3
51	Epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: A systematic review and meta-regression. European Journal of Internal Medicine, 2022, 103, 84-94.	2.2	13
52	Atrial Fibrillation and the Risk of Early-Onset Dementia: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 2022, 11, .	3.7	17
53	Atrial fibrillation pattern and factors affecting the progression to permanent atrial fibrillation. Internal and Emergency Medicine, 2021, 16, 1131-1140.	2.0	27
54	The importance of adherence and persistence with oral anticoagulation treatment in patients with atrial fibrillation. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f81-f83.	3.0	8

#	ARTICLE	IF	CITATIONS
55	Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 229-237.	4.0	16
56	Prognostic value of implantable defibrillatorâ€œcomputed respiratory disturbance index: The DASAP-HF study. Heart Rhythm, 2021, 18, 374-381.	0.7	2
57	Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. Europace, 2021, 23, 174-183.	1.7	74
58	Trans-catheter valve implantation and patient outcomes: Focus on the kidney. European Journal of Internal Medicine, 2021, 83, 88-89.	2.2	1
59	Atrial fibrillation in dilated cardiomyopathy: Outcome prediction from an observational registry. International Journal of Cardiology, 2021, 323, 140-147.	1.7	26
60	Prevention of longâ€œlasting atrial fibrillation through antitachycardia pacing in DDDR pacemakers. International Journal of Clinical Practice, 2021, 75, e13820.	1.7	1
61	Grey zones in the practice of permanent cardiac pacing: The case of preventive pacing for improving rhythm control in atrial fibrillation. International Journal of Clinical Practice, 2021, 75, e13728.	1.7	1
62	Permanent Atrial Fibrillation as the Terminal Stage of a Chronic Disease: Palliative Care Needs to be Considered in Selected Patients with Markedly Impaired Quality of Life. Cardiology, 2021, 146, 397-399.	1.4	1
63	Anticoagulant selection in relation to the SAME-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry. Hellenic Journal of Cardiology, 2021, 62, 152-157.	1.0	2
64	Cognitive impairment in patients with atrial fibrillation: Implications for outcome in a cohort study. International Journal of Cardiology, 2021, 323, 83-89.	1.7	15
65	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	2.2	5,583
66	Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. Thrombosis and Haemostasis, 2021, 121, 140-149.	3.4	22
67	Seventeen-year trend (2001â€œ2017) in pacemaker and implantable cardioverter-defibrillator utilization based on hospital discharge database data: An analysis by age groups. European Journal of Internal Medicine, 2021, 84, 38-45.	2.2	27
68	The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A Novel Approach to In-Depth Characterization (Rather than Classification) of Atrial Fibrillation. Thrombosis and Haemostasis, 2021, 121, 270-278.	3.4	118
69	Sudden cardiac death in dialysis patients: different causes and management strategies. Nephrology Dialysis Transplantation, 2021, 36, 396-405.	0.7	39
70	Inhibition of lysyl oxidase stimulates TGF- β ² signaling and metalloproteinases-2 and -9 expression and contributes to the disruption of ascending aorta in rats: protection by propylthiouracil. Heart and Vessels, 2021, 36, 738-747.	1.2	3
71	High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes. Current Pharmaceutical Design, 2021, 27, 263-275.	1.9	27
72	Red Cell Distribution Width: A Routinely Available Biomarker with Important Clinical Implications in Patients with Atrial Fibrillation. Current Pharmaceutical Design, 2021, 27, 3901-3912.	1.9	12

#	ARTICLE	IF	CITATIONS
73	Clinical Factors Associated with Atrial Fibrillation Detection on Single-Time Point Screening Using a Hand-Held Single-Lead ECG Device. <i>Journal of Clinical Medicine</i> , 2021, 10, 729.	2.4	30
74	Infective endocarditis with perivalvular abscess complicated by septic embolization with acute ST-segment elevation myocardial infarction and peripheral ischemia. <i>IJC Heart and Vasculature</i> , 2021, 32, 100711.	1.1	1
75	Percutaneous pericardiocentesis for pericardial effusion: predictors of mortality and outcomes. <i>Internal and Emergency Medicine</i> , 2021, 16, 1771-1777.	2.0	11
76	Echocardiographic Left Ventricular Mass Assessment: Correlation between 2D-Derived Linear Dimensions and 3-Dimensional Automated, Machine Learning-Based Methods in Unselected Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 1279.	2.4	7
77	Biomarkers in atrial fibrillation: a constant search for simplicity, practicality, and cost-effectiveness. <i>Kardiologia Polska</i> , 2021, 79, 243-245.	0.6	4
78	The challenge to improve knowledge on the interplay between subclinical atrial fibrillation, atrial cardiomyopathy, and atrial remodeling. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 1364-1366.	1.7	7
79	Long-term outcomes of postoperative atrial fibrillation following non cardiac surgery: A systematic review and metanalysis. <i>European Journal of Internal Medicine</i> , 2021, 85, 27-33.	2.2	21
80	Red blood cell distribution width in patients undergoing transcatheter aortic valve implantation: Implications for outcomes. <i>International Journal of Clinical Practice</i> , 2021, 75, e14153.	1.7	4
81	Worldwide Survey of COVID-19 Associated Arrhythmias. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009458.	4.8	127
82	Organization and procedures in contemporary catheter ablation centres: data from the 2018 Italian Catheter Ablation Registry. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 631-636.	1.5	6
83	Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes. <i>Cardiovascular Research</i> , 2021, 117, 1-21.	3.8	67
84	Beyond the 2020 guidelines on atrial fibrillation of the European society of cardiology. <i>European Journal of Internal Medicine</i> , 2021, 86, 1-11.	2.2	40
85	Clinical Value of Complex Echocardiographic Left Ventricular Hypertrophy Classification Based on Concentricity, Mass, and Volume Quantification. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 667984.	2.4	6
86	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021, 23, 1612-1676.	1.7	494
87	In- and out-of-hospital mortality for myocardial infarction during the first wave of the COVID-19 pandemic in Emilia-Romagna, Italy: A population-based observational study. <i>Lancet Regional Health - Europe</i> , The, 2021, 3, 100055.	5.6	36
88	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>Europace</i> , 2021, 23, 1324-1342.	1.7	18
89	Remote monitoring and telemedicine in heart failure: implementation and benefits. <i>Current Cardiology Reports</i> , 2021, 23, 55.	2.9	29
90	Infections associated with cardiac electronic implantable devices: economic perspectives and impact of the TYRX,¢ antibacterial envelope. <i>Europace</i> , 2021, 23, iv33-iv44.	1.7	14

#	ARTICLE	IF	CITATIONS
91	Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry. <i>Journal of Clinical Medicine</i> , 2021, 10, 2879.	2.4	7
92	Procedural complications in patients undergoing catheter ablation for atrial fibrillation: let's talk about sex. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 427-428.	4.0	1
93	Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: a systematic review and meta-analysis. <i>Heart</i> , 2021, 107, 1630-1636.	2.9	38
94	Clinical Phenotype Classification of Atrial Fibrillation Patients Using Cluster Analysis and Associations with Trial-Adjudicated Outcomes. <i>Biomedicines</i> , 2021, 9, 843.	3.2	15
95	Cost-Effectiveness Analyses of an Absorbable Antibacterial Envelope for Use in Patients at Increased Risk of Cardiac Implantable Electronic Device Infection in Germany, Italy, and England. <i>Value in Health</i> , 2021, 24, 930-938.	0.3	19
96	Cost-minimization analysis of a wearable cardioverter defibrillator in adult patients undergoing <sc>ICD</sc> explant procedures: Clinical and economic implications. <i>Clinical Cardiology</i> , 2021, 44, 1497-1505.	1.8	7
97	Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncologyâ€”Part 1: acute coronary syndromes and acute pericardial diseases. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 947-959.	1.0	37
98	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>European Heart Journal</i> , 2021, 42, 3427-3520.	2.2	899
99	Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. <i>Europace</i> , 2021, 23, 1873-1891.	1.7	10
100	Reshaping of Italian Echocardiographic Laboratories Activities during the Second Wave of COVID-19 Pandemic and Expectations for the Post-Pandemic Era. <i>Journal of Clinical Medicine</i> , 2021, 10, 3466.	2.4	7
101	Screening for Atrial Fibrillation in Relation to Stroke and Mortality Risk. <i>Thrombosis and Haemostasis</i> , 2021, , .	3.4	2
102	Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients. <i>European Heart Journal</i> , 2021, 42, 3541-3554.	2.2	32
103	Updating a simple clinical score predicting incident atrial fibrillation: The CHEST score or more (mCHEST)? <i>European Journal of Internal Medicine</i> , 2021, 90, 27-29.	2.2	3
104	Comparing Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation: A Systematic Review and Meta-Analysis of 81,462 Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 3979.	2.4	34
105	Red Cell Distribution Width and Patient Outcome in Cardiovascular Disease: A â€”Real-Worldâ€” Analysis. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 120.	1.6	9
106	How did COVID-19 affect medical and cardiology journals? A pandemic in literature. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 840-847.	1.5	8
107	Atrial fibrillation is related to higher mortality in COVID-19/SARS-CoV-2 pneumonia infection. <i>Cardiology Journal</i> , 2021, 28, 973-975.	1.2	2
108	Impact of COVID-19 Pandemic on Remote Monitoring of Cardiac Implantable Electronic Devices in Italy: Results of a Survey Promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing). <i>Journal of Clinical Medicine</i> , 2021, 10, 4086.	2.4	23

#	ARTICLE	IF	CITATIONS
109	Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2021, 92, 100-106.	2.2	31
110	Effects of sildenafil on right ventricle remodelling in Portopulmonary hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 70, 102071.	2.6	11
111	Clinical and electrocardiographic characteristics at admission of COVID-19/SARS-CoV2 pneumonia infection. <i>Internal and Emergency Medicine</i> , 2021, 16, 1451-1456.	2.0	24
112	COVID-19 pandemic: complex interactions with the arrhythmic profile and the clinical course of patients with cardiovascular disease. <i>European Heart Journal</i> , 2021, 42, 529-532.	2.2	15
113	Sinergy between drugs and devices in the fight against sudden cardiac death and heart failure. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 110-123.	1.8	20
114	Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 611-621.	1.8	33
115	OUP accepted manuscript. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	3.0	1
116	Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. <i>BMC Medicine</i> , 2021, 19, 256.	5.5	22
117	The Practice of Deep Sedation in Electrophysiology and Cardiac Pacing Laboratories: Results of an Italian Survey Promoted by the AIAC (Italian Association of Arrhythmology and Cardiac Pacing). <i>Journal of Clinical Medicine</i> , 2021, 10, 5035.	2.4	2
118	Cardiac resynchronization therapy: variations across Europe in implant rates and types of implanted devices. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 90-93.	1.5	2
119	Digital literacy as a potential barrier to implementation of cardiology tele-visits after COVID-19 pandemic: the INFO-COVID survey. <i>Journal of Geriatric Cardiology</i> , 2021, 18, 739-747.	0.2	5
120	The Impact of COVID-19 Pandemic and Lockdown Restrictions on Cardiac Implantable Device Recipients with Remote Monitoring. <i>Journal of Clinical Medicine</i> , 2021, 10, 5626.	2.4	9
121	Estimate and reporting of longevity for cardiac implantable electronic devices: a proposal for standardized criteria. <i>Expert Review of Medical Devices</i> , 2021, 18, 1203-1208.	2.8	0
122	Clinical management of electrical storm: a current overview. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 669-679.	1.5	4
123	Role of cardiac imaging in patients undergoing catheter ablation of ventricular tachycardia. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 727-737.	1.5	2
124	444â€fEpidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: a systematic review and meta-regression. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
125	684â€fCardiac troponins and adverse outcomes in European patients with atrial fibrillation: a report from the ESC-EHRA EORP atrial fibrillation general long-term registry. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	1
126	Association between clinical risk scores and mortality in atrial fibrillation: Systematic review and network meta-regression of 669,000 patients. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 633-644.	1.8	26

#	ARTICLE	IF	CITATIONS
127	Are atrial high rate episodes (AHREs) a precursor to atrial fibrillation?. Clinical Research in Cardiology, 2020, 109, 409-416.	3.3	22
128	Obesity Paradox in Atrial Fibrillation: Implications for Outcomes and Relationship with Oral Anticoagulant Drugs. American Journal of Cardiovascular Drugs, 2020, 20, 125-137.	2.2	11
129	Tailored oral anticoagulant prescription in patients with atrial fibrillation: Use and misuse of clinical risk prediction scores. European Journal of Preventive Cardiology, 2020, 27, 726-728.	1.8	5
130	Female sex and stroke in atrial fibrillation: an intriguing relationship. Internal and Emergency Medicine, 2020, 15, 175-179.	2.0	3
131	Temporal patterns of premature atrial complexes predict atrial fibrillation occurrence in bradycardia patients continuously monitored through pacemaker diagnostics. Internal and Emergency Medicine, 2020, 15, 599-606.	2.0	3
132	European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infectionsâ€”endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio. Europace, 2020, 22, 515-549.	1.7	216
133	Managing atrial fibrillation: the need for an individualized approach even in the emergency department. Internal and Emergency Medicine, 2020, 15, 9-12.	2.0	10
134	Shoulder Function After Cardioverter-Defibrillator Implantation: 5-Year Follow-up. Annals of Thoracic Surgery, 2020, 110, 608-614.	1.3	5
135	European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infectionsâ€”endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European	1.4	111
136	â€”Real-worldâ€” observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). Europace, 2020, 22, 831-832.	1.7	18
137	Radiotherapy-induced malfunctions of cardiac implantable electronic devices in cancer patients. Internal and Emergency Medicine, 2020, 15, 967-973.	2.0	9
138	Cost-Effectiveness of an Antibacterial Envelope for Cardiac Implantable Electronic Device Infection Prevention in the US Healthcare System From the WRAP-IT Trial. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008503.	4.8	39
139	<p>Cardiac Electronic Devices: Future Directions and Challenges</p>. Medical Devices: Evidence and Research, 2020, Volume 13, 325-338.	0.8	12
140	Consumer-led screening for atrial fibrillation using consumer-facing wearables, devices and apps: A survey of health care professionals by AF-SCREEN international collaboration. European Journal of Internal Medicine, 2020, 82, 97-104.	2.2	38
141	Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action. Internal and Emergency Medicine, 2020, 15, 1573-1576.	2.0	43
142	Continuous monitoring of <scp>sleepâ€”disordered</scp> breathing with pacemakers: Indexes for risk stratification of atrial fibrillation and risk of stroke. Clinical Cardiology, 2020, 43, 1609-1615.	1.8	4
143	Optimal Use of Echocardiography in Management of Thrombosis After Anterior Myocardial Infarction. Echocardiography, 2020, 37, 1287-1295.	0.9	7
144	Degree of left ventricular dilatation at endâ€”diastole: Correlation and prognostic utility of quantitative volumes by 2Dâ€”echocardiography versus linear dimensions in patients with asymptomatic aortic regurgitation. Echocardiography, 2020, 37, 1336-1344.	0.9	1

#	ARTICLE	IF	CITATIONS
145	Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 587-600.	1.5	5
146	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>European Journal of Heart Failure</i> , 2020, 22, 2349-2369.	7.1	101
147	Impact of COVID-19 pandemic on the clinical activities related to arrhythmias and electrophysiology in Italy: results of a survey promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing). <i>Internal and Emergency Medicine</i> , 2020, 15, 1445-1456.	2.0	66
148	Temporary transvenous cardiac pacing. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 420-427.	1.5	6
149	What do we do about atrial high rate episodes?. <i>European Heart Journal Supplements</i> , 2020, 22, O42-O52.	0.1	29
150	Influence of BMI and geographical region on prescription of oral anticoagulants in newly diagnosed atrial fibrillation: The GLORIA-AF Registry Program. <i>European Journal of Internal Medicine</i> , 2020, 80, 35-44.	2.2	9
151	Complicated myocardial infarction in a 99-year-old lady in the era of COVID-19 pandemic: from the need to rule out coronavirus infection to emergency percutaneous coronary angioplasty. <i>Internal and Emergency Medicine</i> , 2020, 15, 835-839.	2.0	6
152	Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. <i>Drugs</i> , 2020, 80, 1065-1083.	10.9	22
153	Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era. <i>European Journal of Internal Medicine</i> , 2020, 77, 158-160.	2.2	62
154	The Euro Heart Survey and EURObservational Research Programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20 years. <i>Internal and Emergency Medicine</i> , 2020, 15, 1183-1192.	2.0	25
155	Effects of Anti-vitamin k oral anticoagulants on bone and cardiovascular health. <i>European Journal of Internal Medicine</i> , 2020, 79, 1-11.	2.2	10
156	Effect on mortality of different routes of administration and loading dose of aspirin in patients with ST-segment elevation acute myocardial infarction treated with primary angioplasty. <i>Coronary Artery Disease</i> , 2020, 31, 348-353.	0.7	1
157	Driving restriction in patients with cardiac implantable electronic devices: an overview of worldwide regulations. <i>Expert Review of Medical Devices</i> , 2020, 17, 297-308.	2.8	4
158	Cardiac implantable electrical devices in patients with hypertrophic cardiomyopathy: single center implant data extracted from the Swedish pacemaker and ICD registry. <i>Scandinavian Cardiovascular Journal</i> , 2020, 54, 239-247.	1.2	6
159	Intrahospital organizational model of remote monitoring data sharing, for a global management of patients with cardiac implantable electronic devices: a document of the Italian Association of Arrhythmology and Cardiac Pacing. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 171-181.	1.5	28
160	Cytokine Profile in Striated Muscle Laminopathies: New Promising Biomarkers for Disease Prediction. <i>Cells</i> , 2020, 9, 1532.	4.1	8
161	Kidney dysfunction and short term all-cause mortality after transcatheter aortic valve implantation. <i>European Journal of Internal Medicine</i> , 2020, 81, 32-37.	2.2	9
162	European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardiol. <i>European Heart Journal</i> , 2020, 41, 2012-2032.	2.2	120

#	ARTICLE	IF	CITATIONS
163	Cardiac arrest: The need for integrated multi-disciplinary actions for a continuum of care both in acute and at long-term. <i>European Journal of Internal Medicine</i> , 2020, 74, 37-39.	2.2	0
164	Anticoagulation to prevent ischaemic stroke in patients with atrial fibrillation: a complex scenario including underdiagnosis, undertreatment, or underdosing of oral anticoagulants. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 95-97.	4.0	6
165	Atrial fibrillation and remote monitoring through cardiac implantable electronic devices in heart failure patients. <i>European Journal of Heart Failure</i> , 2020, 22, 554-556.	7.1	10
166	One-year clinical events and management of patients with atrial fibrillation hospitalized in cardiology centers: Data from the BLITZ-AF study. <i>European Journal of Internal Medicine</i> , 2020, 74, 55-60.	2.2	7
167	A giant right coronary artero-venous fistula revealed by an integrated multimodality imaging approach. <i>Internal and Emergency Medicine</i> , 2020, 15, 1331-1332.	2.0	0
168	Impact of Cardiac Implantable Electronic Device Infection. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008280.	4.8	41
169	From meta-analysis to the individual patient with atrial fibrillation and coronary artery disease: the complexity of antithrombotic treatment in real-world clinical practice and the need for a tailored approach. <i>European Journal of Internal Medicine</i> , 2020, 77, 27-29.	2.2	2
170	Infection of Cardiac Implantable Electrical Devices: An Emerging Epidemiological Issue. , 2020, , 1-16.		0
171	Prevention of Device Infection: Procedural Aspects, Drugs, and Preventive Tools. , 2020, , 177-208.		0
172	COVID-19 pandemic: usefulness of telemedicine in management of arrhythmias in elderly people. <i>Journal of Geriatric Cardiology</i> , 2020, 17, 593-596.	0.2	7
173	Cardioversion of recent-onset atrial fibrillation: current evidence, practical considerations, and controversies in a complex clinical scenario. <i>Kardiologia Polska</i> , 2020, 78, 1088-1098.	0.6	5
174	European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). <i>Europace</i> , 2019, 21, 7-8.	1.7	72
175	Management of atrial fibrillation in the emergency room and in the cardiology ward: the BLITZ AF study. <i>Europace</i> , 2019, 21, 230-238.	1.7	27
176	Lead choice in cardiac implantable electronic devices: an Italian survey promoted by AIAC (Italian) Tj ETQq0 0 0 rgBT J Overlock 10 Tf 50	2.8	4
177	Infective endocarditis in patients with cardiac implantable electronic devices: Impact of comorbidities on outcome. <i>European Journal of Internal Medicine</i> , 2019, 66, e9-e10.	2.2	5
178	Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation. <i>Europace</i> , 2019, 21, 1764-1775.	1.7	20
179	Oral anticoagulation for subclinical atrial tachyarrhythmias detected by implantable cardiac devices: an international survey of the AF-SCREEN Group. <i>International Journal of Cardiology</i> , 2019, 296, 65-70.	1.7	14
180	Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019, 381, 385-388.	27.0	3

#	ARTICLE	IF	CITATIONS
181	Favorable Trend of Implantable Cardioverterâ€Defibrillator Service Life in a Large Singleâ€Nation Population: Insights From 10â€Year Analysis of the Italian Implantable Cardioverterâ€Defibrillator Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e012759.	3.7	13
182	Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA). <i>Europace</i> , 2019, 21, 1603-1604.	1.7	61
183	Screening for atrial fibrillation: Need for an integrated, structured approach. <i>European Journal of Internal Medicine</i> , 2019, 67, 33-35.	2.2	12
184	Occurrence of atrial fibrillation in pacemaker patients and its association with sleep apnea and heart rate variability. <i>European Journal of Internal Medicine</i> , 2019, 68, 13-17.	2.2	5
185	Usefulness of Red Cells Distribution Width to Predict Worse Outcomes in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 124, 1561-1567.	1.6	13
186	Cancer and atrial fibrillation. Author's reply. <i>European Journal of Internal Medicine</i> , 2019, 62, e24-e25.	2.2	0
187	Clinical practice and implementation of guidelines for the prevention, diagnosis and management of cardiac implantable electronic device infections: results of a worldwide survey under the auspices of the European Heart Rhythm Association. <i>Europace</i> , 2019, 21, 1270-1279.	1.7	49
188	Imaging functional stress test for stable chest pain symptoms in patients at low pretest probability of coronary artery disease: Current practice and longâ€term outcome. <i>Echocardiography</i> , 2019, 36, 1095-1102.	0.9	5
189	Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association. <i>European Journal of Heart Failure</i> , 2019, 21, 690-693.	7.1	3
190	Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. <i>Europace</i> , 2019, 21, 1013-1022.	1.7	47
191	Remodeling classification system considering left ventricular volume in patients with aortic valve stenosis: Association with adverse cardiovascular outcomes. <i>Echocardiography</i> , 2019, 36, 639-650.	0.9	6
192	Cardiomyopathy associated with longâ€term right ventricular pacing: an intriguing clinical issue. <i>European Journal of Heart Failure</i> , 2019, 21, 652-654.	7.1	3
193	Reactive atrialâ€based antitachycardia pacing therapy reduces atrial tachyarrhythmias. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 970-979.	1.2	22
194	Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. <i>Canadian Journal of Cardiology</i> , 2019, 35, 619-633.	1.7	48
195	Atrial high rate episodes in patients with cardiac implantable electronic devices: implications for clinical outcomes. <i>Clinical Research in Cardiology</i> , 2019, 108, 1034-1041.	3.3	15
196	EHRA White Paper: knowledge gaps in arrhythmia managementâ€status 2019. <i>Europace</i> , 2019, 21, 993-994.	1.7	40
197	Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). <i>Europace</i> , 2019, 21, 844-845.	1.7	68
198	Differences in cardiac phenotype and natural history of laminopathies with and without neuromuscular onset. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 263.	2.7	12

#	ARTICLE	IF	CITATIONS
199	Nationwide survey on the current practice of ventricular tachycardia ablation. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 597-605.	1.5	2
200	Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2427-2436.	3.0	66
201	Searching for Atrial Fibrillation Poststroke. <i>Circulation</i> , 2019, 140, 1834-1850.	1.6	184
202	The 12-lead ECG: a continuous reference for the cardiologist. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 459-463.	1.5	5
203	The role of physical activity in individuals with cardiovascular risk factors: an opinion paper from Italian Society of Cardiology-Emilia Romagna-Marche and SIC-Sport. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 631-639.	1.5	43
204	Clinical and organizational management of cardiac implantable electronic device replacements. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 531-541.	1.5	12
205	Neuro-arrhythmology. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 731-744.	1.5	11
206	Home care for heart failure: can caregiver education prevent hospital admissions? A randomized trial in primary care. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 30-38.	1.5	15
207	Contribution of PET imaging to mortality risk stratification in candidates to lead extraction for pacemaker or defibrillator infection: a prospective single center study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 194-205.	6.4	45
208	Corrected QT Interval Prolongation in Psychopharmacological Treatment and Its Modulation by Genetic Variation. <i>Neuropsychobiology</i> , 2019, 77, 67-72.	1.9	13
209	Cardiac resynchronization therapy: need to synchronize patients and device longevities with comorbidities. <i>Europace</i> , 2019, 21, 683-685.	1.7	2
210	Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF). <i>American Journal of Cardiology</i> , 2019, 123, 592-597.	1.6	10
211	New classification of geometric patterns considering left ventricular volume in patients with chronic aortic valve regurgitation: Prevalence and association with adverse cardiovascular outcomes. <i>Echocardiography</i> , 2019, 36, 38-46.	0.9	7
212	Direct oral anticoagulants vs non-vitamin K antagonist in atrial fibrillation: A prospective, propensity score adjusted cohort study. <i>European Journal of Internal Medicine</i> , 2019, 62, 9-16.	2.2	13
213	Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2019, 40, 1541-1550.	2.2	88
214	Effect of PR interval and pacing mode on persistent atrial fibrillation incidence in dual chamber pacemaker patients: a sub-study of the international randomized MINERVA trial. <i>Europace</i> , 2019, 21, 636-644.	1.7	20
215	Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality. <i>European Journal of Internal Medicine</i> , 2019, 59, 27-33.	2.2	31
216	Effects of cardiac resynchronization therapy on right ventricular function during rest and exercise, as assessed by radionuclide angiography, and on NT-proBNP levels. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 123-132.	2.1	8

#	ARTICLE	IF	CITATIONS
217	Atrial fibrillation in patients with cardiac implantable electronic devices: new perspectives with important clinical implications. <i>Kardiologia Polska</i> , 2019, 77, 1119-1120.	0.6	12
218	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardiaca y Electrofisiologia (SOLAECE). <i>European Heart Journal</i> , 2018, 39, ehw455.	2.2	28
219	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>European Heart Journal</i> , 2018, 39, 2314-2325.	2.2	186
220	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632.	1.7	55
221	Clinically oriented device programming in bradycardia patients: part 2 (atrioventricular blocks and Tj ETQq1 1 0.784314 rgBT /Overlock	1.5	17
222	Clinically oriented device programming in bradycardia patients: part 1 (sinus node disease). Proposals from AIAC (Italian Association of Arrhythmology and Cardiac Pacing). <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 161-169.	1.5	22
223	Role of cardiovascular imaging in cardiac resynchronization therapy. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 211-222.	1.5	13
224	Physical Activity Measured by Implanted Devices Predicts Atrial Arrhythmias and Patient Outcome: Results of IMPLANTED (Italian Multicentre Observational Registry on Patients With Implantable) Tj ETQq0 0 0 rgBT /Overlock 24 Tf 50 4	1.5	24
225	Cardiac resynchronization therapy: How did consensus guidelines from Europe and the United States evolve in the last 15 years?. <i>International Journal of Cardiology</i> , 2018, 261, 119-129.	1.7	18
226	The struggle against infections of cardiac implantable electrical devices: the burden of costs requires new personalized solutions. <i>Europace</i> , 2018, 20, 1877-1879.	1.7	11
227	Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 172-179.	3.0	31
228	Letter responding to Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Societat Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE)â€™ Authorsâ€™ reply. <i>Europace</i> , 2018, 20, 893-894.	1.7	1
229	Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e005820.	4.8	50
230	Contemporary stroke prevention strategies in 11â€™%096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. <i>Europace</i> , 2018, 20, 747-757.	1.7	118
231	Five year trends (2008â€™2012) in cardiac implantable electrical device utilization in five European nations: a case study in cross-country comparisons using administrative databases. <i>Europace</i> , 2018, 20, 643-653.	1.7	20
232	Antiarrhythmic drugsâ€™ clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). <i>Europace</i> , 2018, 20, 731-732an.	1.7	144
233	Overweight and obesity in patients with atrial fibrillation: Sex differences in 1â€™year outcomes in the EORPâ€™AF General Pilot Registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 566-572.	1.7	23
234	European Society of Cardiology: Cardiovascular Disease Statistics 2017. <i>European Heart Journal</i> , 2018, 39, 508-579.	2.2	595

#	ARTICLE	IF	CITATIONS
235	Management of patients with cardiac implantable electronic devices (CIED) undergoing radiotherapy. <i>International Journal of Cardiology</i> , 2018, 255, 175-183.	1.7	57
236	Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations. <i>European Journal of Heart Failure</i> , 2018, 20, 1472-1481.	7.1	39
237	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018, 20, 395-407.	1.7	95
238	Elevated TGF β 2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes. <i>Nucleus</i> , 2018, 9, 337-349.	2.2	25
239	In Memoriam Luigi Padeletti: an Italian Scientist, an Italian Maestro, an Italian Friend. <i>Europace</i> , 2018, 20, 1063-1064.	1.7	0
240	2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHRs. <i>Europace</i> , 2018, 20, 1217-1217.	1.7	243
241	Atrial fibrillation and prediction of mortality by conventional clinical score systems according to the setting of care. <i>International Journal of Cardiology</i> , 2018, 261, 73-77.	1.7	7
242	European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRs). <i>Europace</i> , 2018, 20, 895-896.	1.7	24
243	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , 2018, 20, 1231-1242.	1.7	194
244	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1330-1393.	2.2	1,576
245	Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation. <i>Europace</i> , 2018, 20, 243-252.	1.7	33
246	Role of the tricuspid regurgitation after mitralclip and transcatheter aortic valve implantation: a systematic review and meta-analysis. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 654-659.	1.2	31
247	Cardiac resynchronization therapy and electrical storm: results of the OBSERVational registry on long-term outcome of ICD patients (OBSERVO-ICD). <i>Europace</i> , 2018, 20, 979-985.	1.7	26
248	Risk stratification of cardiovascular and heart failure hospitalizations using integrated device diagnostics in patients with a cardiac resynchronization therapy defibrillator. <i>Europace</i> , 2018, 20, e69-e77.	1.7	29
249	Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 147-151.	2.6	3
250	Implantable cardioverter-defibrillator-computed respiratory disturbance index accurately identifies severe sleep apnea: The DASAP-HF study. <i>Heart Rhythm</i> , 2018, 15, 211-217.	0.7	16
251	The "Subtle" connection between development of cardiac implantable electrical device infection and survival after complete system removal: An observational prospective multicenter study. <i>International Journal of Cardiology</i> , 2018, 250, 146-149.	1.7	30
252	Predictors of long-term survival free from relapses after extraction of infected CIED. <i>Europace</i> , 2018, 20, 1018-1027.	1.7	43

#	ARTICLE	IF	CITATIONS
253	Extending survival by reducing sudden death with implantable cardioverter-defibrillators: a challenging clinical issue in non-ischaemic and ischaemic cardiomyopathies. <i>European Journal of Heart Failure</i> , 2018, 20, 420-426.	7.1	9
254	Atrial fibrillation prevention: an appraisal of current evidence. <i>Heart</i> , 2018, 104, 882-887.	2.9	31
255	Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden. <i>Heart Rhythm</i> , 2018, 15, 376-383.	0.7	86
256	Management of cardiopulmonary disease in patients with systemic sclerosis. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 513-515.	1.5	3
257	Health care cost analysis of enhanced pacing modalities in bradycardia patients: Portuguese case study on the results of the MINERVA trial. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2018, 37, 973-978.	0.2	2
258	Comparison of cryoballoon and radiofrequency ablation techniques for atrial fibrillation: a meta-analysis. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 725-738.	1.5	14
259	Health care cost analysis of enhanced pacing modalities in bradycardia patients: Portuguese case study on the results of the MINERVA trial. <i>Revista Portuguesa De Cardiologia</i> , 2018, 37, 973-978.	0.5	2
260	Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1483-1488.	2.0	5
261	Is ventricular sensing always right, when it is left?. <i>Clinical Cardiology</i> , 2018, 41, 1238-1245.	1.8	11
262	Cardiac resynchronization therapy in the real world: need to upgrade outcome research. <i>European Journal of Heart Failure</i> , 2018, 20, 1469-1471.	7.1	9
263	Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. <i>European Journal of Internal Medicine</i> , 2018, 55, 28-34.	2.2	51
264	Cardiac involvement in systemic sclerosis. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 393-395.	1.5	5
265	Pacemaker-detected severe sleep apnoea predicts new-onset atrial fibrillation: Author's reply. <i>Europace</i> , 2018, 20, 2047-2048.	1.7	0
266	Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA. <i>Europace</i> , 2018, 20, 1882-1897.	1.7	27
267	Impact of pacemaker longevity on expected device replacement rates: Results from computer simulations based on a multicenter registry (ESSENTIAL). <i>Clinical Cardiology</i> , 2018, 41, 1185-1191.	1.8	6
268	Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry. <i>International Journal of Cardiology</i> , 2018, 271, 68-74.	1.7	30
269	Variations in clinical management of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation according to different equations for estimating renal function. <i>Internal and Emergency Medicine</i> , 2018, 13, 1059-1067.	2.0	17
270	Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes. <i>Nucleus</i> , 2018, 9, 442-459.	2.2	17

#	ARTICLE	IF	CITATIONS
271	A closer look into the complexity of our practice: Outcome research for transvenous temporary cardiac pacing. <i>International Journal of Cardiology</i> , 2018, 271, 117-118.	1.7	4
272	Antithrombotic Therapy for Atrial Fibrillation. <i>Chest</i> , 2018, 154, 1121-1201.	0.8	718
273	Long-term progression of rhythm and conduction disturbances in pacemaker recipients: findings from the Pacemaker Expert Programming study. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 357-365.	1.5	9
274	Efficacy of cardiac resynchronization therapy in patients with isolated ventricular noncompaction with dilated cardiomyopathy: a systematic review of the literature. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 324-328.	1.5	10
275	Meta-analysis of Clinical Outcomes of Electrical Cardioversion and Catheter Ablation in Patients with Atrial Fibrillation and Chronic Kidney Disease. <i>Current Pharmaceutical Design</i> , 2018, 24, 2794-2801.	1.9	12
276	12-year Temporal Trend in Referral Pattern and Test Results of Stress Echocardiography in a Tertiary Care Referral Center with Moderate Volume Activities and Cath-lab Facility. <i>Journal of Cardiovascular Echography</i> , 2018, 28, 32.	0.4	4
277	European Society of Cardiology-Proposed Diagnostic Echocardiographic Algorithm in Elective Patients with Clinical Suspicion of Infective Endocarditis: Diagnostic Yield and Prognostic Implications in Clinical Practice. <i>Journal of Cardiovascular Echography</i> , 2018, 28, 26.	0.4	4
278	How to RESPOND to the quest to increase the effectiveness of cardiac resynchronization therapy?. <i>European Heart Journal</i> , 2017, 38, ehw595.	2.2	3
279	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>Europace</i> , 2017, 19, euw242.	1.7	67
280	Reduction in unnecessary ventricular pacing fails to affect hard clinical outcomes in patients with preserved left ventricular function: a meta-analysis. <i>Europace</i> , 2017, 19, euw221.	1.7	26
281	Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. <i>Europace</i> , 2017, 19, euw150.	1.7	32
282	Effect of fixed-rate vs. rate-RESPONSive pacing on exercise capacity in patients with permanent, refractory atrial fibrillation and left ventricular dysfunction treated with atrioventricular junction aBLation and biventricular pacing (RESPONSIBLE): a prospective, multicentre, randomized, single-blind study. <i>Europace</i> , 2017, 19, euw035.	1.7	12
283	Patient outcome after implant of a cardioverter defibrillator in the "real world": the key role of co-morbidities. <i>European Journal of Heart Failure</i> , 2017, 19, 387-390.	7.1	9
284	Can we predict new AF occurrence in single-chamber ICD patients? Insights from an observational investigation. <i>International Journal of Cardiology</i> , 2017, 230, 275-280.	1.7	8
285	Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide. <i>Advances in Therapy</i> , 2017, 34, 620-637.	2.9	8
286	The Changing Landscape for Stroke Prevention in AF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 777-785.	2.8	244
287	Investigating Regional Variation of Cardiac Implantable Electrical Device Implant Rates in European Healthcare Systems: What Drives Differences?. <i>Health Economics (United Kingdom)</i> , 2017, 26, 30-45.	1.7	24
288	Oral loading of propafenone: restoring its role before restoring rhythm. <i>Europace</i> , 2017, 19, 1903-1903.	1.7	0

#	ARTICLE	IF	CITATIONS
289	Evaluating adherence to non-vitamin-K antagonist oral anticoagulants in post-approval observational studies of patients with atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2017, 33, 1175-1177.	1.9	3
290	Cardiac resynchronization therapy in the real world: need to focus on implant rates, patient selection, co-morbidities, type of devices, and complications. <i>European Heart Journal</i> , 2017, 38, 2129-2131.	2.2	10
291	Screening for Atrial Fibrillation. <i>Circulation</i> , 2017, 135, 1851-1867.	1.6	453
292	Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. <i>American Heart Journal</i> , 2017, 189, 137-145.	2.7	258
293	Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 120, 482-490.	2.5	10
294	Atrial antitachycardia pacing and atrial remodeling: A substudy of the international, randomized MINERVA trial. <i>Heart Rhythm</i> , 2017, 14, 1476-1484.	0.7	12
295	Hypertension and Cardiac Arrhythmias: Executive Summary of a Consensus Document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRs) and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLEACE). <i>European Heart Journal - Cardiovascular Electrophysiology</i> , 2017, 2, 225-250.	3.0	50
296	Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRs) and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLEACE). <i>Europace</i> , 2017, 19, 891-911.	1.7	124
297	Pacemaker-detected severe sleep apnea predicts new-onset atrial fibrillation. <i>Europace</i> , 2017, 19, 1937-1943.	1.7	28
298	The effects of gender on electrical therapies for the heart: procedural considerations, results and complications. <i>Europace</i> , 2017, 19, 1911-1921.	1.7	3
299	The effects of gender on electrical therapies for the heart: physiology, epidemiology, and access to therapies. <i>Europace</i> , 2017, 19, 1418-1426.	1.7	16
300	The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden. <i>Europace</i> , 2017, 19, 1767-1775.	1.7	5
301	The Italian subcutaneous implantable cardioverter-defibrillator survey: S-ICD, why not?. <i>Europace</i> , 2017, 19, 1826-1832.	1.7	22
302	Electrical treatment of atrial arrhythmias in heart failure patients implanted with a dual defibrillator CRT device. Results from the TRADE-HF study. <i>International Journal of Cardiology</i> , 2017, 236, 181-186.	1.7	1
303	Prevalence and clinical significance of left bundle branch block according to classical or strict definition criteria in permanent pacemaker patients. <i>Clinical Cardiology</i> , 2017, 40, 377-382.	1.8	3
304	Adoption Decisions for Medical Devices in the Field of Cardiology: Results from a European Survey. <i>Health Economics (United Kingdom)</i> , 2017, 26, 124-144.	1.7	21
305	Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation. <i>Europace</i> , 2017, 19, 1439-1448.	1.7	47
306	Arrhythmias Originating in the Atria. <i>Cardiac Electrophysiology Clinics</i> , 2017, 9, 383-409.	1.7	14

#	ARTICLE	IF	CITATIONS
307	Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase. <i>International Journal of Cardiology</i> , 2017, 248, 166-172.	1.7	9
308	Emery-Dreifuss Muscular Dystrophy-Associated Mutant Forms of Lamin A Recruit the Stress Responsive Protein Ankrd2 into the Nucleus, Affecting the Cellular Response to Oxidative Stress. <i>Cellular Physiology and Biochemistry</i> , 2017, 42, 169-184.	1.6	14
309	Management of atrial high-rate episodes detected by cardiac implanted electronic devices. <i>Nature Reviews Cardiology</i> , 2017, 14, 701-714.	13.7	98
310	The wearable cardioverter-defibrillator: current technology and evolving indications. <i>Europace</i> , 2017, 19, 335-345.	1.7	65
311	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>European Journal of Preventive Cardiology</i> , 2017, 24, 4-40.	1.8	83
312	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardiac y Electrofisiologia (SOLAECE). <i>Europace</i> , 2017, 19, 465-511.	1.7	118
313	Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MORECARE multicentre randomized controlled trial. <i>European Journal of Heart Failure</i> , 2017, 19, 416-425.	7.1	165
314	Cardiac Resynchronization Therapy. <i>Heart Failure Clinics</i> , 2017, 13, 117-137.	2.1	12
315	Device-detected subclinical atrial tachyarrhythmias: definition, implications and management" an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Cardaca y ElectrofisiologAa (SOLAECE). <i>Europace</i> , 2017, 19, 1556-1578.	1.7	186
316	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardaca y ElectrofisiologAa (SOLAECE). <i>Europace</i> , 2017, 19, 1589-1623.	1.7	208
317	document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Cardaca y ElectrofisiologAa (SOLAECE). <i>Europace</i> , 2017, 19, 1589-1623.	1.7	107
318	Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Es. Thrombosis and Haemostasis, 2017, 117, 2215-2236.	3.4	41
319	Establishing and Managing a Device Clinic and Database. , 2017, , 1191-1200.		0
320	Outcomes with Dronedaron in Atrial Fibrillation: What Differences Between Real-World Practice and Trials? A Meta-Analysis and Meta-Regression Analysis. <i>Current Pharmaceutical Design</i> , 2017, 23, 944-951.	1.9	13
321	Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias. <i>Arrhythmia and Electrophysiology Review</i> , 2016, 5, 210.	2.4	4
322	BLOCK HF. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 306-308.	1.5	5
323	Predictors of nonsimultaneous interventricular delay at cardiac resynchronization therapy optimization. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 299-305.	1.5	4
324	Effect of telemonitoring of cardiac implantable electronic devices on healthcare utilization: a meta-analysis of randomized controlled trials in patients with heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 195-204.	7.1	100

#	ARTICLE	IF	CITATIONS
325	Left Ventricular Reverse Remodeling Elicited by a Quadripolar Lead: Results from the Multicenter Per4mer Study. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 250-260.	1.2	8
326	Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. <i>Scientific Reports</i> , 2016, 6, 30271.	3.3	51
327	Automatic management of atrial and ventricular stimulation in a contemporary unselected population of pacemaker recipients: the ESSENTIAL Registry. <i>Europace</i> , 2016, 18, 1551-1560.	1.7	17
328	Beat-to-beat variability of P-wave in patients suffering from atrial fibrillation. , 2016, 2016, 770-773.		2
329	Electrocardiographic Eligibility for Subcutaneous Implantable Cardioverter Defibrillator: Evaluation during Bicycle Exercise. <i>Heart Lung and Circulation</i> , 2016, 25, 476-483.	0.4	14
330	Atrial fibrillation burden and atrial fibrillation type: Clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation. <i>Vascular Pharmacology</i> , 2016, 83, 26-35.	2.1	66
331	Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2016, 118, 432-439.	1.6	45
332	â€Real-worldâ€™ atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-â€Atrial Fibrillation General Registry Pilot Phase. <i>Europace</i> , 2016, 19, euw112.	1.7	55
333	The Impact of Diabetes and Comorbidities on the Outcome of Heart Failure Patients Treated With Cardiac Resynchronization Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	4.8	1
334	Tailored treatment strategies: a new approach for modern management of atrial fibrillation. <i>Journal of Internal Medicine</i> , 2016, 279, 457-466.	6.0	9
335	Switching among Equivalents in Chronic Cardiovascular Therapies: â€Real Worldâ€™ Data from Italy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 118, 63-69.	2.5	1
336	A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation. <i>Journal of Internal Medicine</i> , 2016, 279, 467-476.	6.0	13
337	Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. <i>American Heart Journal</i> , 2016, 181, 83-91.	2.7	38
338	Psychological correlates, allostatic overload and clinical course in patients with implantable cardioverter defibrillator (ICD). <i>International Journal of Cardiology</i> , 2016, 220, 360-364.	1.7	20
339	Prognostic implications of mitral regurgitation in patients after cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2016, 18, 1060-1068.	7.1	30
340	Clinically guided pacemaker choice and setting: pacemaker expert programming study. <i>Europace</i> , 2016, 19, euw256.	1.7	7
341	P-wave Variability and Atrial Fibrillation. <i>Scientific Reports</i> , 2016, 6, 26799.	3.3	34
342	Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives. <i>Europace</i> , 2016, 18, 1507-1513.	1.7	7

#	ARTICLE	IF	CITATIONS
343	Cardiac device therapy in patients with left ventricular dysfunction and heart failure: â€realâ€worldâ€™™ data on longâ€term outcomes (mortality, hospitalizations, days alive and out of hospital). European Journal of Heart Failure, 2016, 18, 693-702.	7.1	45
344	Implant rates of cardiac implantable electrical devices in Europe: A systematic literature review. Health Policy, 2016, 120, 1-15.	3.0	44
345	Effect of Cardiac Resynchronization Therapy on Left Atrial Size and Function as Expressed by Speckle Tracking 2-Dimensional Strain. American Journal of Cardiology, 2016, 118, 237-243.	1.6	21
346	Implantable cardioverter-defibrillator programming and electrical storm: Results of the OBSERVational registry On long-term outcome of ICD patients (OBSERVO-ICD). Heart Rhythm, 2016, 13, 1987-1992.	0.7	38
347	The ventricular ectopic QRS interval (VEQSI): Diagnosis of arrhythmogenic right ventricular cardiomyopathy in patients with incomplete disease expression. Heart Rhythm, 2016, 13, 1504-1512.	0.7	13
348	Cardiac Resynchronization Therapy Withâ€Quadrupolar Electrode Lead Decreases Complications at 6 Months. JACC: Clinical Electrophysiology, 2016, 2, 212-220.	3.2	37
349	EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. European Heart Journal Cardiovascular Imaging, 2016, 17, 355-383.	1.2	233
350	Reduction of inappropriate anti-tachycardia pacing therapies and shocks by a novel suite of detection algorithms in heart failure patients with cardiac resynchronization therapy defibrillators: a historical comparison of a prospective database. Europace, 2016, 18, 1391-1398.	1.7	4
351	Atrial Fibrillation and Aging. Chest, 2016, 149, 301-302.	0.8	9
352	â€Real-worldâ€™™ management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programmeâ€Atrial Fibrillation (EORP-AF) General Pilot Registry. Europace, 2016, 18, 648.1-657.	1.7	61
353	Battery drain in daily practice and medium-term projections on longevity of cardioverter-defibrillators: an analysis from a remote monitoring database. Europace, 2016, 18, 1366-1373.	1.7	21
354	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace, 2016, 18, 159-183.	1.7	135
355	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace, 2016, 18, 37-50.	1.7	121
356	Ventricular antitachycardia pacing therapy in patients with heart failure implanted with a cardiac resynchronization therapy defibrillator device: Efficacy, safety, and impact on mortality. Heart Rhythm, 2016, 13, 472-480.	0.7	6
357	Cardiac Resynchronization Therapy: State of the Art. Cardiac Electrophysiology Clinics, 2015, 7, xvii-xviii.	1.7	1
358	Against all odds: Targeted pacing site for resynchronization therapy by venoplasty and active fixation lead. Indian Heart Journal, 2015, 67, 574-576.	0.5	0
359	Age-Related Differences in Presentation, Treatment, and Outcome of Patients Withâ€Atrial Fibrillation in Europe. JACC: Clinical Electrophysiology, 2015, 1, 326-334.	3.2	52
360	Validation of a simple risk stratification tool for patients implanted with Cardiac Resynchronization Therapy: the <scp>VALIDâ€CRT</scp> risk score. European Journal of Heart Failure, 2015, 17, 717-724.	7.1	41

#	ARTICLE	IF	CITATIONS
361	Detect Long-term Complications After ICD Replacement (DECODE): Rationale and Study Design of a Multicenter Italian Registry. <i>Clinical Cardiology</i> , 2015, 38, 577-584.	1.8	17
362	New left ventricular active fixation lead: The experience of lead extraction. <i>Indian Heart Journal</i> , 2015, 67, S97-S99.	0.5	22
363	The Epidemiologic Threat of Atrial Fibrillation. <i>Chest</i> , 2015, 147, 9-10.	0.8	8
364	Remote monitoring of cardiac implantable electrical devices in Europe: quo vadis?. <i>Europace</i> , 2015, 17, 674-676.	1.7	12
365	Non-valvular atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 491-496.	1.5	17
366	Clinical management of electromagnetic interferences in patients with pacemakers and implantable cardioverter-defibrillators. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 704.	1.5	10
367	Cardiac resynchronization therapy and cardiac sympathetic function. <i>European Journal of Clinical Investigation</i> , 2015, 45, 792-799.	3.4	18
368	Management of atrial fibrillation in bradyarrhythmias. <i>Nature Reviews Cardiology</i> , 2015, 12, 337-349.	13.7	26
369	Effects of enhanced pacing modalities on health care resource utilization and costs in bradycardia patients: An analysis of the randomized MINERVA trial. <i>Heart Rhythm</i> , 2015, 12, 1192-1200.	0.7	11
370	Holter ECG for pacemaker/defibrillator carriers: what is its role in the era of remote monitoring?. <i>Heart</i> , 2015, 101, 1272-1278.	2.9	14
371	Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). <i>Europace</i> , 2015, 17, 1747-1769.	1.7	119
372	Difficult decision making in the management of patients with atrial fibrillation and acute coronary syndrome or invasive cardiovascular interventions: new recommendations for daily practice. <i>Europace</i> , 2015, 17, 1319-1322.	1.7	5
373	Asymptomatic Atrial Fibrillation: Clinical Correlates, Management, and Outcomes in the EORP-AF Pilot General Registry. <i>American Journal of Medicine</i> , 2015, 128, 509-518.e2.	1.5	242
374	Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2015, 17, 194-206.	1.7	41
375	Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine) Trial. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1033-1041.	0.7	63
376	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2015, 17, 1169-1196.	1.7	138
377	Repolarization effects of multiple-cycle chemotherapy and predictors of QTc prolongation: a prospective female cohort study on >2000 ECGs. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1001-1009.	1.9	11
378	New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial. <i>Heart Rhythm</i> , 2015, 12, 1717-1725.	0.7	56

#	ARTICLE	IF	CITATIONS
379	Inappropriate shock for myopotential over-sensing in a patient with subcutaneous ICD. Indian Heart Journal, 2015, 67, 56-59.	0.5	16
380	Heart failure in patients with atrial fibrillation in Europe: a report from the <scp>EURObservational</scp> Research Programme Pilot survey on Atrial Fibrillation. European Journal of Heart Failure, 2015, 17, 570-582.	7.1	68
381	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace, 2015, 17, euv319.	1.7	635
382	Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace, 2015, 17, 1777-1786.	1.7	128
383	Cardiac Resynchronization Therapy. Cardiac Electrophysiology Clinics, 2015, 7, 673-693.	1.7	4
384	Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHS). Europace, 2015, 17, 1197-1214.	1.7	160
385	Heterogeneous response of cardiac sympathetic function to cardiac resynchronization therapy in heart failure documented by 11[C]-hydroxy-ephedrine and PET/CT. Nuclear Medicine and Biology, 2015, 42, 858-863.	0.6	11
386	Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace, 2015, 17, 24-31.	1.7	164
387	Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. EuroIntervention, 2015, 10, 1015-1021.	3.2	21
388	Device-detected atrial fibrillation and risk for stroke: an analysis of >10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted) Tj ETQq0 0 0 rgBTz/Ovzok 10 Tf 50 3	1.7	110
389	Statistics on the use of cardiac electronic devices and electrophysiological procedures in 55 ESC countries: 2013 report from the European Heart Rhythm Association (EHRA). Europace, 2014, 16, i1-i78.	1.7	46
390	Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial. European Heart Journal, 2014, 35, 2352-2362.	2.2	111
391	Left ventricular lead stabilization to retain cardiac resynchronization therapy at long term: when is it advisable?. Europace, 2014, 16, 533-540.	1.7	28
392	Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF) Tj ETQq0 0 0 rgBTz/Ovzok 10 Tf 50 3	1.7	110
393	The OPTI-MIND study: a prospective, observational study of pacemaker patients according to pacing modality and primary indications. Europace, 2014, 16, 689-697.	1.7	15
394	Cardiac resynchronization therapy. Journal of Cardiovascular Medicine, 2014, 15, 269-272.	1.5	6
395	Ventricular rate monitoring as a tool to predict and prevent atrial fibrillation-related inappropriate shocks in heart failure patients treated with cardiac resynchronisation therapy defibrillators. Heart, 2014, 100, 848-854.	2.9	14
396	Prevention of infections in cardiovascular implantable electronic devices beyond the antibiotic agent. Journal of Cardiovascular Medicine, 2014, 15, 554-564.	1.5	27

#	ARTICLE	IF	CITATIONS
397	Cardiac resynchronization therapy. Journal of Cardiovascular Medicine, 2014, 15, 147-154.	1.5	17
398	Determinants of All-Cause Mortality in Different Age Groups in Patients With Severe Systolic Left Ventricular Dysfunction Receiving an Implantable Cardioverter Defibrillator (from the Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 T 1691-1696.	1.6	18
399	Role of 18F-FDG PET/CT in the diagnosis of infective endocarditis in patients with an implanted cardiac device: a prospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1617-1623.	6.4	79
400	â€œReal-Worldâ€™ Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey. American Journal of Medicine, 2014, 127, 519-529.e1.	1.5	144
401	New devices in heart failure: an European Heart Rhythm Association report: Developed by the European Heart Rhythm Association; Endorsed by the Heart Failure Association. Europace, 2014, 16, 109-128.	1.7	62
402	AF burden is important - fact or fiction?. International Journal of Clinical Practice, 2014, 68, 444-452.	1.7	53
403	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. European Heart Journal, 2014, 35, 3155-3179.	2.2	490
404	Pacing-induced torsades de pointes after the short-long-short sequence in a patient with a biventricular defibrillator: What is the mechanism?. Heart Rhythm, 2014, 11, 728-731.	0.7	1
405	2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy. Revista Espanola De Cardiologia (English Ed), 2014, 67, 58.	0.6	54
406	Cost-effectiveness of implantable cardioverter-defibrillator in today's world. Indian Heart Journal, 2014, 66, S101-S104.	0.5	15
407	Stroke/Thromboembolism and Intracranial Hemorrhage in a Real-world Atrial Fibrillation Population. Chest, 2014, 146, 1073-1080.	0.8	7
408	Asymptomatic Lone Atrial Fibrillation - How can we Detect the Arrhythmia?. Current Pharmaceutical Design, 2014, 21, 659-666.	1.9	29
409	¹¹ C-mHED for PET / CT: Principles of Synthesis, Methodology and First Clinical Applications. Current Radiopharmaceuticals, 2014, 7, 79-83.	0.8	5
410	Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden. European Journal of Clinical Pharmacology, 2013, 69, 715-720.	1.9	6
411	Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients. Heart Rhythm, 2013, 10, 214-218.	0.7	15
412	Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillators in Children and Adolescents With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2013, 61, 1527-1535.	2.8	240
413	Acute changes in electromechanical parameters during different pacing configurations using a quadripolar left ventricular lead. Journal of Interventional Cardiac Electrophysiology, 2013, 38, 61-69.	1.3	10
414	Assessing the outcomes of implantable cardioverter defibrillator treatment in a real world setting: results from hospital record data. BMC Health Services Research, 2013, 13, 100.	2.2	8

#	ARTICLE	IF	CITATIONS
415	The use of imaging for electrophysiological and devices procedures: a report from the first European Heart Rhythm Association Policy Conference, jointly organized with the European Association of Cardiovascular Imaging (EACVI), the Council of Cardiovascular Imaging and the European Society of Cardiac Radiology. <i>Europace</i> , 2013, 15, 927-936.	1.7	38
416	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2013, 15, 1540-1556.	1.7	125
417	Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants. <i>Pharmacoeconomics</i> , 2013, 31, 971-980.	3.3	32
418	From lead management to implanted patient management: systematic review and meta-analysis of the last 15 years of experience in lead extraction. <i>Expert Review of Medical Devices</i> , 2013, 10, 551-573.	2.8	78
419	Short-spaced dipole for managing phrenic nerve stimulation in patients with CRT: The â€œphrenic nerve mapping and stimulation EPâ€¢catheter study. <i>Heart Rhythm</i> , 2013, 10, 39-45.	0.7	18
420	Implantation of cardioverter-defibrillator: Effects on shoulder function. <i>International Journal of Cardiology</i> , 2013, 168, 294-299.	1.7	18
421	Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation. <i>JACC: Heart Failure</i> , 2013, 1, 500-507.	4.1	147
422	Response to the Letter from Dr Bertini. <i>Europace</i> , 2013, 15, 613-614.	1.7	0
423	Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. <i>European Heart Journal</i> , 2013, 34, 1869-1874.	2.2	85
424	Left ventricular pacing rate lower than expected during manual pacing threshold test in a biventricular defibrillator. <i>Europace</i> , 2013, 15, 826-826.	1.7	2
425	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). <i>Europace</i> , 2013, 15, 1070-1118.	1.7	908
426	Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon. <i>Europace</i> , 2013, 15, 1453-1462.	1.7	47
427	Letter by Gasparini and Boriani Regarding Article, â€œCardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation: Results From the Resynchronization for Ambulatory Heart Failure Trial (RAFT)â€¢. <i>Circulation: Heart Failure</i> , 2013, 6, e22.	3.9	4
428	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>European Heart Journal</i> , 2013, 34, 2281-2329.	2.2	2,176
429	Predicting the Quality of Anticoagulation During Warfarin Therapy. <i>Chest</i> , 2013, 144, 1437-1438.	0.8	11
430	Incidence and Predictors of Postoperative Atrial Fibrillation in Kidney Transplant Recipients. <i>Transplantation</i> , 2013, 96, 981-986.	1.0	22
431	The MONitoring Resynchronization dEVICES and CARdiac patiEnts (MORE-CARE) Randomized Controlled Trial: Phase 1 Results on Dynamics of Early Intervention With Remote Monitoring. <i>Journal of Medical Internet Research</i> , 2013, 15, e167.	4.3	83
432	Atrial Fibrillation in Patients with Cardiac Resynchronization Therapy: Clinical Management and Outcome. <i>Journal of Atrial Fibrillation</i> , 2013, 5, 748.	0.5	0

#	ARTICLE	IF	CITATIONS
433	On the resolution of ECG acquisition systems for the reliable analysis of the P-wave. <i>Physiological Measurement</i> , 2012, 33, N11-N17.	2.1	10
434	Identifying the patient who FADES away prior to appropriate ICD intervention. <i>Heart</i> , 2012, 98, 833-834.	2.9	0
435	Improving Thromboprophylaxis Using Atrial Fibrillation Diagnostic Capabilities in Implantable Cardioverter-Defibrillators. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 182-188.	2.2	33
436	Meta-analysis of randomized controlled trials evaluating left ventricular vs. biventricular pacing in heart failure: effect on all-cause mortality and hospitalizations. <i>European Journal of Heart Failure</i> , 2012, 14, 652-660.	7.1	45
437	Cost-effectiveness of cardiac resynchronisation therapy. <i>Heart</i> , 2012, 98, 1828-1836.	2.9	31
438	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options—a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2012, 14, 8-27.	1.7	193
439	First prospective, multi-centre clinical experience with a novel left ventricular quadripolar lead. <i>Europace</i> , 2012, 14, 365-372.	1.7	79
440	The EHRA White Book. <i>Europace</i> , 2012, 14, ii1-ii55.	1.7	25
441	Atrial Fibrillation. <i>Chest</i> , 2012, 141, 290-292.	0.8	0
442	Globalization of the Epidemiologic, Clinical, and Financial Burden of Atrial Fibrillation. <i>Chest</i> , 2012, 142, 1368-1370.	0.8	21
443	Changes in global longitudinal strain during rest and exercise in patients treated with cardiac resynchronization therapy. <i>Clinical Physiology and Functional Imaging</i> , 2012, 32, 310-316.	1.2	4
444	Arrhythmia discrimination by physician and defibrillator: Importance of atrial channel. <i>International Journal of Cardiology</i> , 2012, 154, 134-140.	1.7	16
445	Prophylactic cardioverter defibrillator utilization in the "real world": A conundrum. <i>International Journal of Cardiology</i> , 2012, 156, 123-124.	1.7	3
446	Winning the war, far, in developing countries. Novel anticoagulants as a new weapon against stroke. <i>International Journal of Cardiology</i> , 2012, 154, 336-337.	1.7	2
447	Short-term onset of fatal pulmonary toxicity in a patient treated with intravenous amiodarone for post-operative atrial fibrillation. <i>International Journal of Cardiology</i> , 2012, 159, e1-e4.	1.7	7
448	The "europe and stick" and the "safety snare": Two new techniques for tricky lead extractions. <i>International Journal of Cardiology</i> , 2012, 157, 449-451.	1.7	3
449	QRS pattern and improvement in right and left ventricular function after cardiac resynchronization therapy: a radionuclide study. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 27.	1.7	5
450	Influence of time between last myocardial infarction and prophylactic implantable defibrillator implant on device detections and therapies. "Routine Practice" data from the SEARCH MI registry. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 72.	1.7	4

#	ARTICLE	IF	CITATIONS
451	The empowerment of translational research: lessons from laminopathies. Orphanet Journal of Rare Diseases, 2012, 7, 37.	2.7	7
452	Massive Pulmonary Embolism with Acute Coronary Syndrome-like Electrocardiogram Mimicking Acute Left Main Coronary Artery Obstruction. Journal of Emergency Medicine, 2012, 43, e255-e258.	0.7	5
453	Transcatheter aortic valve implantation with a self-expanding nitinol bioprosthesis. Catheterization and Cardiovascular Interventions, 2012, 79, 712-719.	1.7	37
454	Impact of Mitral Regurgitation on the Outcome of Patients Treated with CRT: Data from the InSync ICD Italian Registry. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 146-154.	1.2	17
455	Relevance of Monitoring Atrial Fibrillation in Clinical Practice. Arrhythmia and Electrophysiology Review, 2012, 1, 54.	2.4	5
456	Device-Detected Atrial Tachyarrhythmias Predict Adverse Outcome in Real-World Patients With Implantable Biventricular Defibrillators. Journal of the American College of Cardiology, 2011, 57, 167-172.	2.8	116
457	Treatment of atrial fibrillation with a dual defibrillator in heart failure patients (TRADE HF): protocol for a randomized clinical trial. Trials, 2011, 12, 44.	1.6	6
458	Role of atrial fibrillation after transcatheter closure of patent foramen ovale in patients with or without cryptogenic stroke. International Journal of Cardiology, 2011, 146, 17-21.	1.7	17
459	Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Thrombosis and Haemostasis, 2011, 106, 1012-1019..	3.4	81
460	Phrenic stimulation management in CRT patients: are we there yet?. Current Opinion in Cardiology, 2011, 26, 12-16.	1.8	23
461	Clinical Management of Atrial Fibrillation. Chest, 2011, 140, 843-845.	0.8	7
462	Targeting the Arrhythmogenic Substrate in Atrial Fibrillation: Focus on Structural Remodeling. Current Drug Targets, 2011, 12, 263-286.	2.1	11
463	QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus. British Journal of Clinical Pharmacology, 2011, 72, 839-841.	2.4	7
464	Peri-operative management of patients taking antithrombotic therapy: need for an integrated proactive approach. International Journal of Clinical Practice, 2011, 65, 236-239.	1.7	2
465	Long-Term RV Threshold Behavior by Automated Measurements: Safety is the Standpoint of Pacemaker Longevity!. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 89-95.	1.2	23
466	Response:. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 389-390.	1.2	0
467	Management of Phrenic Stimulation in CRT Patients over the Long Term: Still an Unmet Need ?. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 1201-1208.	1.2	21
468	The Challenge of Preventing Stroke in Elderly Patients With Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2011, 22, 31-33.	1.7	0

#	ARTICLE	IF	CITATIONS
469	Changes in exercise capacity induced by heart transplantation: prognostic and therapeutic implications. Scandinavian Journal of Medicine and Science in Sports, 2011, 21, 519-525.	2.9	8
470	Comparison of the Usefulness of Cardiac Resynchronization Therapy in Three Age-Groups ($65, 65-74$). Tj ETQq0 0 0 rgBT /Overlock 10 1510-1516.	1.6	30
471	How to truly value implantable cardioverter-defibrillators technology: Up-front cost or daily cost?. International Journal of Technology Assessment in Health Care, 2011, 27, 201-206.	0.5	15
472	Effects of cardiac resynchronization therapy on myocardial contractile reserve during exercise. European Journal of Heart Failure, 2011, 13, 406-411.	7.1	6
473	Incidence and clinical relevance of uncontrolled ventricular rate during atrial fibrillation in heart failure patients treated with cardiac resynchronization therapy. European Journal of Heart Failure, 2011, 13, 868-876.	7.1	53
474	Effects of cardiac resynchronisation therapy on dilated cardiomyopathy with isolated ventricular non-compaction. Heart, 2011, 97, 295-300.	2.9	55
475	Device therapy and hospital reimbursement practices across European countries: a heterogeneous scenario. Europace, 2011, 13, ii59-ii65.	1.7	50
476	Excimer laser lead extraction by femoral approach. Europace, 2011, 13, 757-759.	1.7	9
477	Healthcare personnel resource burden related to in-clinic follow-up of cardiovascular implantable electronic devices: a European Heart Rhythm Association and Eucomed joint survey. Europace, 2011, 13, 1166-1173.	1.7	33
478	Cardiac resynchronization therapy: a cost or an investment?. Europace, 2011, 13, ii32-ii38.	1.7	19
479	Health technology assessment: what is it? Current status and perspectives in the field of electrophysiology. Europace, 2011, 13, ii49-ii53.	1.7	22
480	Economic evaluation in cardiology. Europace, 2011, 13, ii3-ii8.	1.7	26
481	Health economics and the European Heart Rhythm Association. Europace, 2011, 13, ii1-ii2.	1.7	6
482	Improving Stroke Risk Stratification Using the CHADS ₂ and CHA ₂ DS ₂ -VASc Risk Scores in Patients With Paroxysmal Atrial Fibrillation by Continuous Arrhythmia Burden Monitoring. Stroke, 2011, 42, 1768-1770.	2.0	176
483	Long-Term Complications Related to Biventricular Defibrillator Implantation. Circulation, 2011, 123, 2526-2535.	1.6	80
484	From lead management to implanted patient management: indications to lead extraction in pacemaker and cardioverter-defibrillator systems. Expert Review of Medical Devices, 2011, 8, 235-255.	2.8	47
485	Balancing the Risk of Hemorrhage vs Thromboembolism in Patients With Atrial Fibrillation. Chest, 2010, 138, 1032-1033.	0.8	13
486	Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. , 2010, 125, 196-218.		126

#	ARTICLE	IF	CITATIONS
487	Radionuclide Angiographic Determination of Regional Left Ventricular Systolic Function During Rest and Exercise in Patients With Nonischemic Cardiomyopathy Treated With Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2010, 106, 389-394.	1.6	5
488	Effect of Cardiac Resynchronization Therapy on Subendo- and Subepicardial Left Ventricular Twist Mechanics and Relation to Favorable Outcome. <i>American Journal of Cardiology</i> , 2010, 106, 682-687.	1.6	14
489	Role of drugs and devices in patients at risk of sudden cardiac death. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 575-594.	1.9	15
490	Actual Pacemaker Longevity: The Benefit of Stimulation by Automatic Capture Verification. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2010, 33, 873-881.	1.2	47
491	Interventricular Delay Optimization: A Comparison among Three Different Echocardiographic Methods. <i>Echocardiography</i> , 2010, 27, 38-43.	0.9	7
492	Long-term Follow-up of Patients with Syncope Evaluated by Head-up Tilt Test. <i>Annals of Noninvasive Electrocardiology</i> , 2010, 15, 101-106.	1.1	7
493	Trial-generated profiles for implantation of electrical devices in outpatients with heart failure: real-world prevalence and 1-year outcome. <i>Journal of Evaluation in Clinical Practice</i> , 2010, 16, 82-91.	1.8	9
494	Prediction of Cardiac Resynchronization Therapy Response. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, 86-93.	2.6	20
495	Prophylactic Implantable Defibrillator in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia and No Prior Ventricular Fibrillation or Sustained Ventricular Tachycardia. <i>Circulation</i> , 2010, 122, 1144-1152.	1.6	272
496	Prediction of atrial fibrillation in patients with an implantable cardioverter-defibrillator and heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 1101-1110.	7.1	34
497	Exercise intolerance in chronic heart failure: mechanisms and therapies. Part I. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 637-642.	2.8	107
498	A subcutaneous ICD preliminary results. <i>Nature Reviews Cardiology</i> , 2010, 7, 543-544.	13.7	0
499	P-wave characteristics after electrical external cardioversion: Predictive indexes of relapse. , 2010, 2010, 3442-5.		1
500	'Pill-in-the-pocket' treatment for recent-onset atrial fibrillation. <i>Heart</i> , 2010, 96, 1605-1606.	2.9	0
501	Health economics and outcomes research: a new challenge and field of action for the European Heart Rhythm Association. <i>Europace</i> , 2010, 12, 601-603.	1.7	19
502	Delayed asymptomatic migration of an implantable cardioverter-defibrillator lead to the costophrenic angle. <i>Europace</i> , 2010, 12, 1126-1126.	1.7	0
503	Implantable electrical devices for prevention of sudden cardiac death: data on implant rates from a 'real world' regional registry. <i>Europace</i> , 2010, 12, 1224-1230.	1.7	25
504	Cardiac resynchronization therapy: is systole all that matters?. <i>Europace</i> , 2010, 12, 1209-1210.	1.7	2

#	ARTICLE	IF	CITATIONS
505	Management of patients receiving implantable cardiac defibrillator shocks: Recommendations for acute and long-term patient management. <i>Europace</i> , 2010, 12, 1673-1690.	1.7	105
506	Exercise intolerance in chronic heart failure: mechanisms and therapies. Part II. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 643-648.	2.8	49
507	Atrial fibrillation: Adverse effects of "pill-in-the-pocket" treatment and propafenone-carvedilol interaction. <i>International Journal of Cardiology</i> , 2010, 140, 242-243.	1.7	10
508	Incompatibility between intravenous amiodarone and heparin in an infant. <i>International Journal of Cardiology</i> , 2010, 145, e70-e73.	1.7	6
509	A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: The Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial. <i>American Heart Journal</i> , 2010, 159, 1052-1058.e1.	2.7	85
510	The MONitoring Resynchronization dEVICES and CARdiac patiEnts (MORE-CARE) study: Rationale and design. <i>American Heart Journal</i> , 2010, 160, 42-48.	2.7	32
511	La tachicardiomiopatia: una revisione della letteratura. <i>Italian Journal of Medicine</i> , 2010, 4, 92-98.	0.3	1
512	Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment. <i>Heart</i> , 2010, 96, 546-549.	2.9	49
513	Implanted biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT [Role of long detection window programming in patients with Left Ventricular dysfunction, Non-ischemic Etiology in primary prevention treated with a biventricular ICD] study. <i>European Heart Journal</i> , 2009, 30, 2758-2767.	2.2	149
514	Is cardiac resynchronization therapy cost-effective?. <i>Europace</i> , 2009, 11, v93-v97.	1.7	17
515	Effectiveness of cardiac resynchronization therapy in heart failure patients with valvular heart disease: comparison with patients affected by ischaemic heart disease or dilated cardiomyopathy. The InSync/InSync ICD Italian Registry. <i>European Heart Journal</i> , 2009, 30, 2275-2283.	2.2	21
516	Expenditure and value for money: the challenge of implantable cardioverter defibrillators. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2009, 102, 349-356.	0.5	22
517	The QRS interval in patients treated with resynchronization therapy: which value?. <i>European Journal of Heart Failure</i> , 2009, 11, 635-637.	7.1	1
518	Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. <i>Europace</i> , 2009, 11, 716-726.	1.7	74
519	Phrenic Stimulation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2009, 2, 402-410.	4.8	114
520	Resolution of atrial thrombosis with heparin in a newborn with atrial flutter. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2009, 98, 1211-1214.	1.5	5
521	Troponin I Rise After Pacemaker Implantation at the Time of "Universal Definition of Myocardial Infarction": <i>American Journal of Cardiology</i> , 2009, 103, 1061-1065.	1.6	11
522	Left Ventricular Rotational Mechanics in Acute Myocardial Infarction and in Chronic (Ischemic and) Tj ETQq0 0 0 rgBTj/Overlock 10 Tf 50	1.6	41

#	ARTICLE	IF	CITATIONS
523	Reply to Reader's Comment: "Electrocardiographic Optimization of Cardiac Resynchronization Devices: Simple, but Not So Simple!" by Mont et al. American Journal of Cardiology, 2009, 103, 1625-1626.	1.6	0
524	Impact of Time to Reperfusion After Acute Myocardial Infarction on Myocardial Damage Assessed by Left Ventricular Longitudinal Strain. American Journal of Cardiology, 2009, 104, 480-485.	1.6	27
525	Prognostic Implications of the Doppler Restrictive Filling Pattern in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2009, 104, 1727-1731.	1.6	93
526	Clinical implications of left superior vena cava persistence in candidates for pacemaker or cardioverter-defibrillator implantation. Heart and Vessels, 2009, 24, 142-146.	1.2	53
527	Automatic Management of Left Ventricular Stimulation: Hints for Technologic Improvement. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 346-353.	1.2	23
528	Decrease in Patient Radiation Exposure by a Tantalum Filter during Electrophysiological Procedures. PACE - Pacing and Clinical Electrophysiology, 2009, 32, S109-S112.	1.2	3
529	A Prospective Randomized Evaluation of VV Delay Optimization in CRT-D Recipients: Echocardiographic Observations from the RHYTHM II ICD Study. PACE - Pacing and Clinical Electrophysiology, 2009, 32, S120-S125.	1.2	50
530	Atrial Fibrillation Therapy in Patients with a CRT Defibrillator with Wireless Telemetry. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 13-23.	1.2	13
531	Response:. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 1361-1362.	1.2	2
532	Presence and Duration of Atrial Fibrillation Detected by Continuous Monitoring: Crucial Implications for the Risk of Thromboembolic Events. Journal of Cardiovascular Electrophysiology, 2009, 20, 241-248.	1.7	341
533	Remote Monitoring of Patients with an Implanted Device and Patients' Outcomes: The Potential for "Win-Win" Dynamics. Journal of Cardiovascular Electrophysiology, 2009, 20, 1252-1254.	1.7	8
534	Effects of Cardiac Resynchronization Therapy on Left Ventricular Twist. Journal of the American College of Cardiology, 2009, 54, 1317-1325.	2.8	61
535	Prediction of Life-threatening Ventricular Tachyarrhythmias and Death in Patients with Previous Myocardial Infarction by Left Ventricular Longitudinal Strain Analysis. Heart Lung and Circulation, 2009, 18, S46.	0.4	0
536	Effect of high-pass filtering on ECG signal on the analysis of patients prone to atrial fibrillation. Annali Dell'Istituto Superiore Di Sanita, 2009, 45, 427-31.	0.4	13
537	Automatic Verification of Ventricular Stimulation: Fusion Management Algorithm. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 64-69.	1.2	7
538	Left Ventricular versus Biventricular Pacing: A Randomized Comparative Study Evaluating Mid-Term Electromechanical and Clinical Effects. Echocardiography, 2008, 25, 141-148.	0.9	18
539	Telecardiology and Remote Monitoring of Implanted Electrical Devices: The Potential for Fresh Clinical Care Perspectives. Journal of General Internal Medicine, 2008, 23, 73-77.	2.6	50
540	Persistent Atrial Fibrillation Worsens Heart Rate Variability, Activity and Heart Rate, as Shown by a Continuous Monitoring by Implantable Biventricular Pacemakers in Heart Failure Patients. Journal of Cardiovascular Electrophysiology, 2008, 19, 693-701.	1.7	27

#	ARTICLE	IF	CITATIONS
541	Comparison of Two Strategies to Reduce Ventricular Pacing in Pacemaker Patients. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 167-176.	1.2	37
542	Heart Transplantation in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2008, 101, 387-392.	1.6	70
543	Interventricular Delay Interval Optimization in Cardiac Resynchronization Therapy Guided by Echocardiography Versus Guided by Electrocardiographic QRS Interval Width. American Journal of Cardiology, 2008, 102, 1373-1377.	1.6	44
544	Local Amyloidosis as a Possible Component of the Atrial Remodeling Accompanying Trial. Journal of the American College of Cardiology, 2008, 51, 2444-2445.	2.8	2
545	Antiarrhythmic Effect of Reverse Ventricular Remodeling Induced by Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2008, 52, 1442-1449.	2.8	96
546	A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: The Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial. American Heart Journal, 2008, 155, 100.e1-100.e9.	2.7	27
547	The Drug And Pace Health clINical Evaluation (DAPHNE) study: A randomized trial comparing sotalol versus β^2 -blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker. American Heart Journal, 2008, 156, 373.e1-373.e8.	2.7	19
548	The MINERVA study design and rationale: A controlled randomized trial to assess the clinical benefit of minimizing ventricular pacing in pacemaker patients with atrial tachyarrhythmias. American Heart Journal, 2008, 156, 445-451.	2.7	24
549	Electrical storm in patients with biventricular implantable cardioverter defibrillator: Incidence, predictors, and prognostic implications. American Heart Journal, 2008, 156, 847-854.	2.7	28
550	Uneventful Right Ventricular Perforation With Displacement of a Pacing Lead Into the Left Thorax. Journal of Cardiothoracic and Vascular Anesthesia, 2008, 22, 423-425.	1.3	9
551	Ventricular dyssynchrony at echo: Detection by two-dimensional tracking and tissue doppler imaging in candidates to biventricular pacing. , 2008, , .		3
552	Letter by Boriani et al Regarding Article, "Death Without Prior Appropriate Implantable Cardioverter-Defibrillator Therapy: A Competing Risk Study" Circulation, 2008, 118, e515; author reply e516.	1.6	0
553	How to assess the efficacy of catheter ablation of atrial fibrillation?. European Heart Journal, 2008, 29, 2183-2184.	2.2	0
554	Exercise stress echocardiography is superior to rest echocardiography in predicting left ventricular reverse remodelling and functional improvement after cardiac resynchronization therapy. European Heart Journal, 2008, 30, 89-97.	2.2	51
555	Case of the month by the EHRA Education committee: exercise-related arrhythmias. Europace, 2008, 10, 235-237.	1.7	1
556	Contribution of morphology discrimination algorithm for improving rhythm discrimination in slow and fast ventricular tachycardia zones in dual-chamber implantable cardioverter-defibrillators. Europace, 2008, 10, 918-925.	1.7	6
557	Cardiac resynchronization therapy during rest and exercise: comparison of two optimization methods. Europace, 2008, 10, 1161-1169.	1.7	36
558	Longevity of implantable cardioverter-defibrillators: implications for clinical practice and health care systems. Europace, 2008, 10, 1288-1295.	1.7	53

#	ARTICLE	IF	CITATIONS
559	A changing scenario in the clinical use of implantable defibrillators: the need for long-term data on lead performance. <i>Europace</i> , 2008, 11, 1-3.	1.7	4
560	Clinical and arrhythmic outcomes after implantation of a defibrillator for primary prevention of sudden death in patients with post-myocardial infarction cardiomyopathy: The Survey to Evaluate Arrhythmia Rate in High-risk MI patients (SEARCH-MI). <i>Europace</i> , 2008, 11, 476-482.	1.7	28
561	Effects of cardiac resynchronization therapy on coronary blood flow: Evaluation by transthoracic Doppler echocardiography. <i>European Journal of Heart Failure</i> , 2008, 10, 514-520.	7.1	17
562	Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia. <i>Current Medicinal Chemistry</i> , 2008, 15, 2472-2517.	2.4	6
563	Atrial fibrillation ablation: beyond electro-mechanical matters. <i>European Heart Journal</i> , 2008, 29, 2818-2819.	2.2	1
564	Effect of ECG filtering on time domain analysis of the P-wave. , 2008, , .		1
565	Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 605-623.	4.1	16
566	Electromechanical effects of cardiac resynchronization therapy during rest and stress in patients with heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 644-650.	7.1	19
567	Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 405-12.	7.4	705
568	Left ventricular pacing by automatic capture verification. <i>Europace</i> , 2007, 9, 1177-1181.	1.7	14
569	Case of polymorphic ventricular tachycardia after stroke necessitating defibrillation. <i>Europace</i> , 2007, 10, 77-78.	1.7	0
570	Implantable cardioverter defibrillators: from evidence of trials to clinical practice. <i>Country Review Ukraine</i> , 2007, 9, 166-173.	0.8	15
571	Evolution of pacing for bradycardia: Autocapture. <i>Country Review Ukraine</i> , 2007, 9, 123-132.	0.8	22
572	Celebrating 50 years of electrical therapies for the heart. <i>Country Review Ukraine</i> , 2007, 9, 11-12.	0.8	1
573	Rate control in patients with pacemaker affected by brady-tachy form of sick sinus syndrome. <i>American Heart Journal</i> , 2007, 154, 193-200.	2.7	10
574	Wide spectrum of presentation and variable outcomes of isolated left ventricular non-compaction. <i>Heart</i> , 2007, 93, 65-71.	2.9	198
575	Industry Pulse. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 243-246.	2.2	0
576	Effects of Cardiac Resynchronization Therapy on Diastolic Function: Evaluation by Radionuclide Angiography. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2007, 30, S43-6.	1.2	2

#	ARTICLE	IF	CITATIONS
577	Duration of P-Wave Is Associated with Atrial Fibrillation Hospitalizations in Patients with Atrial Fibrillation and Paced for Bradycardia. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 961-969.	1.2	9
578	Cardioverter Defibrillators in Primary Prevention of Sudden Cardiac Death: A Cost or an Investment?. Value in Health, 2007, 10, 1-2.	0.3	6
579	Electrical cardioversion for persistent atrial fibrillation or atrial flutter in clinical practice: predictors of long-term outcome. International Journal of Clinical Practice, 2007, 61, 748-756.	1.7	40
580	How, Why, and When May Atrial Defibrillation Find a Specific Role in Implantable Devices? A Clinical Viewpoint. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 422-433.	1.2	11
581	Atrial Threshold Variability: Implications for Automatic Atrial Stimulation Algorithms. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1445-1454.	1.2	22
582	Transvenous Cardioverter-Defibrillator Implantation in a Patient with Tricuspid Mechanical Prosthesis. Journal of Cardiovascular Electrophysiology, 2007, 18, 329-331.	1.7	13
583	Temporal Variability of Atrial Fibrillation in Pacemaker Recipients for Bradycardia: Implications for Crossover Designed Trials, Study Sample Size, and Identification of Responder Patients by Means of Arrhythmia Burden. Journal of Cardiovascular Electrophysiology, 2007, 18, 250-257.	1.7	10
584	Electrophysiologic Manifestations of Ventricular Tachyarrhythmias Provoking Appropriate Defibrillator Interventions in High-Risk Patients with Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2007, 18, 483-487.	1.7	56
585	Plateau Waveform Shape Allows a Much Higher Patient Shock Energy Tolerance in AF Patients. Journal of Cardiovascular Electrophysiology, 2007, 18, 728-734.	1.7	6
586	Painless Shock Therapy: More Than Just an Attempt to Square the Circle?. Journal of Cardiovascular Electrophysiology, 2007, 18, 1101-1103.	1.7	10
587	Cardiac Resynchronization Therapy: Variations in Echo-Guided Optimized Atrioventricular and Interventricular Delays During Follow-Up. Echocardiography, 2007, 24, 933-939.	0.9	49
588	Potential of Medical Treatment, Device Therapy, and Conventional Surgery in Patients Referred for Heart Transplantation. Journal of Cardiac Surgery, 2007, 22, 456-458.	0.7	0
589	Outcome of cardioverter-defibrillator implant in patients with arrhythmogenic right ventricular cardiomyopathy. Heart and Vessels, 2007, 22, 184-192.	1.2	30
590	Cardiac resynchronization therapy in clinical practice: Need for electrical, mechanical, clinical and logistic synchronization. Journal of Interventional Cardiac Electrophysiology, 2007, 17, 215-224.	1.3	16
591	AB7-2. Heart Rhythm, 2006, 3, S13.	0.7	3
592	P1-72. Heart Rhythm, 2006, 3, S131.	0.7	1
593	Randomized comparison of simultaneous biventricular stimulation versus optimized interventricular delay in cardiac resynchronization therapy. American Heart Journal, 2006, 151, 1050-1058.	2.7	169
594	Characteristics of ventricular tachyarrhythmias occurring in ischemic versus nonischemic patients implanted with a biventricular cardioverter-defibrillator for primary or secondary prevention of sudden death. American Heart Journal, 2006, 152, 527.e1-527.e11.	2.7	11

#	ARTICLE	IF	CITATIONS
595	Electrocardiographic remodeling during cardiac resynchronization therapy. <i>International Journal of Cardiology</i> , 2006, 108, 165-170.	1.7	29
596	Acute and chronic haemodynamic effects of biventricular pacing and of switching to different pacing modalities in heart failure patients. <i>International Journal of Cardiology</i> , 2006, 110, 318-323.	1.7	14
597	Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: Time courses and prediction of response. <i>Peptides</i> , 2006, 27, 1776-1786.	2.4	44
598	Role of severe functional mitral regurgitation in predicting electrical remodeling in idiopathic dilated cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 691-695.	1.5	0
599	Relevance of cardioverter defibrillators for the prevention of sudden cardiac death on the timing of heart transplantation. <i>Clinical Transplantation</i> , 2006, 20, 684-688.	1.6	8
600	Reducing Unnecessary Right Ventricular Pacing with the Managed Ventricular Pacing Mode in Patients with Sinus Node Disease and AV Block. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2006, 29, 697-705.	1.2	140
601	Optimization of Pacing Algorithms to Prevent and Treat Supraventricular Tachyarrhythmias. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2006, 29, S61-S72.	1.2	5
602	Primary Prevention of Sudden Cardiac Death: Can We Afford the Cost of Cardioverter-Defibrillators? Data from the Search-MI Registry-Italian Sub-study. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2006, 29, S29-S34.	1.2	8
603	Short QT syndrome and arrhythmogenic cardiac diseases in the young: the challenge of implantable cardioverter-defibrillator therapy for children. <i>European Heart Journal</i> , 2006, 27, 2382-2384.	2.2	24
604	The epidemiological burden of atrial fibrillation: a challenge for clinicians and health care systems The opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> . <i>European Heart Journal</i> , 2006, 27, 893-894.	2.2	85
605	Biventricular vs. left univentricular pacing in heart failure: rationale, design, and endpoints of the B-LEFT HF study. <i>Europace</i> , 2006, 8, 76-80.	1.7	12
606	Role of ventricular autocapture function in increasing longevity of DDDR pacemakers: a prospective study. <i>Europace</i> , 2006, 8, 216-220.	1.7	55
607	Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: the PITAGORA trial. <i>Europace</i> , 2006, 8, 302-305.	1.7	2
608	Randomized comparison between Ramp and Burst+ atrial antitachycardia pacing therapies in patients suffering from sinus node disease and atrial fibrillation and implanted with a DDDR device. <i>Europace</i> , 2006, 8, 465-473.	1.7	14
609	Cardiac Resynchronization Therapy:. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2005, 28, S11-4.	1.2	26
610	Predictors of Atrial Antitachycardia Pacing Efficacy in Patients Affected by Brady-Tachy Form of Sick Sinus Syndrome and Implanted with a DDDR Device. <i>Journal of Cardiovascular Electrophysiology</i> , 2005, 16, 714-723.	1.7	22
611	Atrial Fibrillation in Patients with a Dual Defibrillator: Characteristics of Spontaneous and Induced Episodes and Effect of Ventricular Tachyarrhythmia Induction. <i>Journal of Cardiovascular Electrophysiology</i> , 2005, 16, 974-980.	1.7	3
612	Evaluation of Fusion Beat Detection with a New Ventricular Automatic Capture Algorithm in ICDs. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2005, 28, S263-S266.	1.2	4

#	ARTICLE	IF	CITATIONS
613	Evaluation of the Atrial Evoked Response for Capture Detection with High-Polarization Leads. PACE - Pacing and Clinical Electrophysiology, 2005, 28, S57-S62.	1.2	8
614	Comparison of Induced and Spontaneous Atrial Tachyarrhythmias in Patients with a History of Spontaneous Atrial Tachyarrhythmias. Journal of Cardiovascular Electrophysiology, 2005, 16, 818-822.	1.7	7
615	Implantable Dual-Chamber Defibrillator for the Selective Treatment of Spontaneous Atrial and Ventricular Arrhythmias: Arrhythmia Incidence and Device Performance. Journal of Interventional Cardiac Electrophysiology, 2005, 12, 149-156.	1.3	10
616	Quantification of Fatty Tissue Mass by Magnetic Resonance Imaging in Arrhythmogenic Right Ventricular Dysplasia. Journal of Cardiovascular Electrophysiology, 2005, 16, 256-261.	1.7	12
617	Letter Regarding Article by Bokhari et al, "Long-Term Comparison of the Implantable Cardioverter Defibrillator Versus Amiodarone: Eleven-Year Follow-Up of a Subset of Patients in the Canadian Implantable Defibrillator Study (CIDS)" Circulation, 2005, 111, e26; author reply e26.	1.6	3
618	Pacing with capture verification in candidates for resynchronisation therapy: A feasibility study. Europace, 2005, 7, 255-265.	1.7	8
619	Temporal variability of atrial tachyarrhythmia burden in bradycardia-tachycardia syndrome patients. European Heart Journal, 2005, 26, 165-172.	2.2	30
620	Mechanisms of pain associated with internal defibrillation shocks: Results of a randomized study of shock waveform. Heart Rhythm, 2005, 2, 708-713.	0.7	20
621	Long-term reduction of atrial tachyarrhythmia recurrences in patients paced for bradycardia-tachycardia syndrome. Heart Rhythm, 2005, 2, 1047-1057.	0.7	11
622	P wave dispersion and short-term vs. late atrial fibrillation recurrences after cardioversion. International Journal of Cardiology, 2005, 101, 355-361.	1.7	54
623	Heart failure after myocardial revascularization: Risk markers. International Journal of Cardiology, 2005, 105, 11-14.	1.7	4
624	A controlled study on the effect of verapamil on atrial tachycardia in patients with brady-tachy syndrome implanted with a DDDR pacemaker. International Journal of Cardiology, 2005, 104, 73-76.	1.7	6
625	Dilated-Hypokinetic Evolution of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2005, 46, 1543-1550.	2.8	199
626	Monitored Atrial Fibrillation Duration Predicts Arterial Embolic Events in Patients Suffering From Bradycardia and Atrial Fibrillation Implanted With Antitachycardia Pacemakers. Journal of the American College of Cardiology, 2005, 46, 1913-1920.	2.8	375
627	Prevention of Sudden Death in Hypertrophic Cardiomyopathy. Circulation, 2004, 110, e438-42.	1.6	44
628	Rhythm Control and Increased Risk of Noncardiovascular Death in the Atrial Fibrillation Follow-up Investigation of Rhythm Management Trial. Circulation, 2004, 110, e307-8; author reply e307-8.	1.6	1
629	Closed loop stimulation in prevention of vasovagal syncope. Inotropy controlled pacing in vasovagal syncope (INVASY): a multicentre randomized, single blind, controlled study. Europace, 2004, 6, 538-547.	1.7	97
630	Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. European Heart Journal, 2004, 25, 1237-1241.	2.2	101

#	ARTICLE	IF	CITATIONS
631	Far-Field R Wave Oversensing in Dual Chamber Pacemakers Designed for Atrial Arrhythmia Management: Effect of Pacing Site and Lead Tip to Ring Distance. PACE - Pacing and Clinical Electrophysiology, 2004, 27, 1221-1230.	1.2	24
632	Implications of cardiac resynchronization therapy and prophylactic defibrillator implantation among patients eligible for heart transplantation. American Journal of Cardiology, 2004, 93, 371-373.	1.6	14
633	Clinical and therapeutic implications of troponin elevation in cardiac arrest. American Journal of Cardiology, 2004, 94, 1478.	1.6	2
634	Rate control in AFFIRM: Considerations about the clinical implications. American Journal of Cardiology, 2004, 94, 1104-1105.	1.6	1
635	Atrial Tachyarrhythmia Recurrence Temporal Patterns in Bradycardia Patients Implanted with Antitachycardia Pacemakers. Journal of Cardiovascular Electrophysiology, 2004, 15, 44-51.	1.7	25
636	Pharmacological Cardioversion of Atrial Fibrillation. Drugs, 2004, 64, 2741-2762.	10.9	73
637	Efficacy of internal cardioversion for chronic atrial fibrillation in patients with and without left ventricular dysfunction. International Journal of Cardiology, 2004, 95, 43-47.	1.7	10
638	Cardiac resynchronization by pacing: an electrical treatment of heart failure. International Journal of Cardiology, 2004, 94, 151-161.	1.7	40
639	Increase in QT/QTc dispersion after low energy cardioversion of chronic persistent atrial fibrillation. International Journal of Cardiology, 2004, 95, 245-250.	1.7	9
640	Ventricular fibrillation during sleep in an adolescent with hypertrophic cardiomyopathy: the difficulty of risk stratification and the power of the cardioverter-defibrillator. International Journal of Cardiology, 2004, 97, 143-144.	1.7	0
641	Solution to a Crushing Dosage Problem?. Pediatrics, 2004, 113, 1468-1468.	2.1	1
642	Solution to a Crushing Dosage Problem?. Pediatrics, 2004, 113, 1468-1468.	2.1	0
643	Effect of left ventricular function on long-term left ventricular pacing and sensing threshold. Journal of Interventional Cardiac Electrophysiology, 2003, 9, 21-24.	1.3	18
644	Qrs interval time-related changes and prognosis in heart failure. American Journal of Cardiology, 2003, 91, 514.	1.6	4
645	Cardiac Resynchronization and Implantable Cardioverter Defibrillator Therapy: Preliminary Results from the InSync Implantable Cardioverter Defibrillator Italian Registry. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 148-151.	1.2	17
646	Atrial Evoked Response Integral for Automatic Capture Verification in Atrial Pacing. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 248-252.	1.2	16
647	Abnormal Cardiac Innervation in Patients with Idiopathic Ventricular Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 357-360.	1.2	5
648	Evaluation of a Dual Chamber Implantable Cardioverter Defibrillator for the Treatment of Atrial and Ventricular Arrhythmias. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 461-465.	1.2	14

#	ARTICLE	IF	CITATIONS
649	Rhythm Discrimination by Rate Branch and QRS Morphology in Dual Chamber Implantable Cardioverter Defibrillators. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 466-470.	1.2	33
650	Late Improvement in Ventricular Performance Following Internal Cardioversion for Persistent Atrial Fibrillation:. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 1218-1226.	1.2	7
651	Rate Control in Atrial Fibrillation. Drugs, 2003, 63, 1489-1509.	10.9	39
652	Serial versus isolated assessment of clinical and instrumental parameters in heart failure: prognostic and therapeutic implications. American Heart Journal, 2003, 146, 298-303.	2.7	34
653	Fluttering waves in electrocardiograms recorded in neonatal intensive care unit. International Journal of Cardiology, 2003, 92, 299-301.	1.7	8
654	108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, The Netherlands. Neuromuscular Disorders, 2003, 13, 508-515.	0.6	78
655	Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs. European Journal of Heart Failure, 2003, 5, 419-425.	7.1	28
656	Clinical Relevance of Atrial Fibrillation/Flutter, Stroke, Pacemaker Implant, and Heart Failure in Emery-Dreifuss Muscular Dystrophy. Stroke, 2003, 34, 901-908.	2.0	158
657	Current clinical perspectives on implantable devices for atrial defibrillation. Current Opinion in Cardiology, 2002, 17, 82-89.	1.8	15
658	Oral Loading with Propafenone for Conversion of Recent-Onset Atrial Fibrillation. Drugs, 2002, 62, 415-423.	10.9	25
659	Accelerated QRS widening as an independent predictor of cardiac death or of the need for heart transplantation in patients with congestive heart failure. Journal of Heart and Lung Transplantation, 2002, 21, 899-901.	0.6	54
660	Hypertrophic cardiomyopathy with massive hypertrophy, amiodarone treatment and high defibrillation threshold at cardioverter-defibrillator implant. International Journal of Cardiology, 2002, 83, 171-173.	1.7	8
661	A randomised cross-over study on the haemodynamic effects of oral dofetilide compared with oral sotalol in patients with ischaemic heart disease and sustained ventricular tachycardia. European Journal of Clinical Pharmacology, 2002, 58, 165-169.	1.9	9
662	Atrial Signal Analysis and Defibrillation Threshold Assessment in Chronic Persistent and Reinduced Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2002, 13, 449-454.	1.7	9
663	Atrial Fibrillation Precipitating Sustained Ventricular Tachycardia in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2002, 13, 954-954.	1.7	25
664	Combined Use of Morphology Discrimination, Sudden Onset, and Stability as Discriminating Algorithms in Single Chamber Cardioverter Defibrillators. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 1357-1366.	1.2	42
665	Transvenous internal cardioversion for atrial fibrillation: A randomized comparison between catheters with different coil length. American Heart Journal, 2002, 144, 851-857.	2.7	6
666	Randomized crossover comparison of right atrial appendage pacing versus interatrial septum pacing for prevention of paroxysmal atrial fibrillation in patients with sinus bradycardia. American Heart Journal, 2001, 142, 1047-1055.	2.7	150

#	ARTICLE	IF	CITATIONS
667	Antitachycardia pacing therapy to treat spontaneous atrial tachyarrhythmias: the 7250 dual defibrillator Italian Registry. <i>European Heart Journal Supplements</i> , 2001, 3, P25-P32.	0.1	17
668	Antitachycardia pacing therapies to terminate atrial tachyarrhythmias: the AT500 Italian Registry. <i>European Heart Journal Supplements</i> , 2001, 3, P16-P24.	0.1	14
669	Internal Low Energy Atrial Cardioversion: Efficacy and Safety in Older Patients with Chronic Persistent Atrial Fibrillation. <i>Journal of the American Geriatrics Society</i> , 2001, 49, 80-84.	2.6	2
670	Transvenous Low Energy Internal Cardioversion for Atrial Fibrillation: A Review of Clinical Applications and Future Developments. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001, 24, 99-107.	1.2	23
671	Clinical Evaluation of Morphology Discrimination: An Algorithm for Rhythm Discrimination in Cardioverter Defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001, 24, 994-1001.	1.2	24
672	Impact of consistent atrial pacing algorithm on premature atrial complex number and paroxysmal atrial fibrillation recurrences in brady-tachy syndrome: a randomized prospective cross over study. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2001, 5, 33-44.	1.3	70
673	Neurocardiogenic syncope in selected pediatric patients--natural history during long-term follow-up and effect of prophylactic pharmacological therapy. <i>Cardiovascular Drugs and Therapy</i> , 2001, 15, 161-167.	2.6	6
674	New Options for Pharmacological Conversion of Atrial Fibrillation. , 2001, 5, 195-200.		6
675	Nightmares and Sleep Disturbances with Simvastatin and Metoprolol. <i>Annals of Pharmacotherapy</i> , 2001, 35, 1292-1292.	1.9	21
676	A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. <i>European Heart Journal</i> , 2001, 22, 2180-2191.	2.2	46
677	Cost-effectiveness of implantable cardioverter-defibrillators. <i>European Heart Journal</i> , 2001, 22, 990-996.	2.2	29
678	Left Superior Vena Cava Persistence in Patients Undergoing Pacemaker or Cardioverter-Defibrillator Implantation. <i>Chest</i> , 2001, 120, 139-144.	0.8	224
679	Effects of consistent atrial pacing and atrial rate stabilization - two pacing algorithms to suppress recurrent paroxysmal atrial fibrillation in brady-tachy syndrome. <i>European Heart Journal Supplements</i> , 2001, 3, P7-P15.	0.1	12
680	Repolarization Changes in a Double-blind Crossover Study of Dofetilide Versus Sotalol in the Treatment of Ventricular Tachycardia. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000, 23, 1935-1938.	1.2	8
681	Predictors of Atrial Defibrillation Threshold in Internal Cardioversion. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000, 23, 1898-1901.	1.2	11
682	Benefits in Projected Pacemaker Longevity and in Pacing Related Costs Conferred by Automatic Threshold Tracking. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000, 23, 1783-1787.	1.2	42
683	DDD and single-lead VDD pacing: Evaluation of atrial signal dynamic changes. <i>Clinical Cardiology</i> , 2000, 23, 678-680.	1.8	3
684	Evaluation of Myocardial Injury Following Repeated Internal Atrial Shocks by Monitoring Serum Cardiac Troponin I Levels. <i>Chest</i> , 2000, 118, 342-347.	0.8	42

#	ARTICLE	IF	CITATIONS
685	High defibrillation threshold at cardioverter defibrillator implantation under amiodarone treatment: Favorable effects of D,L -sotalol. Heart and Lung: Journal of Acute and Critical Care, 2000, 29, 412-416.	1.6	16
686	Efficacy of Implantable Cardioverter-Defibrillators for the Prevention of Sudden Death in Patients with Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2000, 342, 365-373.	27.0	953
687	Antiarrhythmic benefits of dual chamber stimulation with rate-response in patients with paroxysmal atrial fibrillation and chronotropic incompetence A prospective, multicentre study. Europace, 1999, 1, 220-225.	1.7	31
688	Low Energy Internal Atrial Cardioversion in Atrial Fibrillation Lasting More Than a Year. PACE - Pacing and Clinical Electrophysiology, 1999, 22, 243-246.	1.2	19
689	Evaluation of atrial refractoriness and atrial fibrillation inducibility immediately after internal cardioversion in patients with chronic persistent atrial fibrillation. Cardiovascular Drugs and Therapy, 1999, 13, 507-511.	2.6	6
690	Transvenous internal cardioversion for atrial fibrillation: a randomized study on defibrillation threshold and tolerability of asymmetrical compared with symmetrical shocks. International Journal of Cardiology, 1999, 71, 63-69.	1.7	12
691	Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation. Journal of the American College of Cardiology, 1999, 33, 333-341.	2.8	57
692	Oral Loading with Propafenone: A Placebo-Controlled Study in Elderly and Nonelderly Patients with Recent Onset Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 2465-2469.	1.2	19
693	Conversion of Recent-Onset Atrial Fibrillation to Sinus Rhythm: Effects of Different Drug Protocols. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 2470-2474.	1.2	88
694	Efficacy and Tolerability in Fully Conscious Patients of Transvenous Low-Energy Internal Atrial Cardioversion for Atrial Fibrillation. American Journal of Cardiology, 1998, 81, 241-244.	1.6	48
695	Clinical reliability of single-lead VDD pacing from evaluation of p-wave sensing under dynamic conditions. American Journal of Cardiology, 1998, 82, 676-679.	1.6	6
696	Pharmacological treatment of atrial fibrillation: a review on prevention of recurrences and control of ventricular response. Archives of Gerontology and Geriatrics, 1998, 27, 127-139.	3.0	11
697	Cardioverter-defibrillator oversensing due to double counting of ventricular tachycardia electrograms. International Journal of Cardiology, 1998, 66, 91-95.	1.7	15
698	Clinical experience with downsized lower energy output implantable cardioverter defibrillators. International Journal of Cardiology, 1998, 66, 261-266.	1.7	9
699	Oral Propafenone To Convert Recent-Onset Atrial Fibrillation in Patients with and without Underlying Heart Disease. Annals of Internal Medicine, 1997, 126, 621.	3.9	145
700	Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. International Journal of Cardiology, 1997, 58, 55-61.	1.7	69
701	Beta-blocker treatment guided by head-up tilt test in neurally mediated syncope. Current Therapeutic Research, 1997, 58, 842-850.	1.2	2
702	Paroxysmal Atrial Fibrillation in Sleep. Sleep, 1997, 20, 396-398.	1.1	38

#	ARTICLE	IF	CITATIONS
703	Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation. <i>American Heart Journal</i> , 1996, 131, 1214-1216.	2.7	49
704	Propafenone for Conversion of Recent-Onset Atrial Fibrillation. <i>Chest</i> , 1995, 108, 355-358.	0.8	106
705	Propafenone in the Treatment of Cardiac Arrhythmias. <i>Drug Safety</i> , 1995, 12, 55-72.	3.2	26
706	Dynamic Electrophysiological Behavior of Human Atria During Paroxysmal Atrial Fibrillation. <i>Circulation</i> , 1995, 92, 1193-1202.	1.6	148
707	Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. <i>American Journal of Cardiology</i> , 1994, 74, 503-505.	1.6	175
708	A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. <i>International Journal of Cardiology</i> , 1994, 43, 305-313.	1.7	121
709	Drugs, gery, Cardioverter Defibrillator: A Decision Based on the Clinical Problem. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1993, 16, 519-527.	1.2	9
710	Î²-Blocking Properties of Propafenone in Extensive Oxidisers: A Study on Heart Rate Behaviour during Holter Monitoring. <i>Drug Investigation</i> , 1993, 6, 25-32.	0.6	7
711	Atrial premature beats coupling interval determines lone paroxysmal atrial fibrillation onset. <i>International Journal of Cardiology</i> , 1992, 36, 87-93.	1.7	59
712	Intravenous administration of propafenone. <i>Journal of the American College of Cardiology</i> , 1992, 19, 1368.	2.8	6
713	Evaluation by Cardiopulmonary Exercise Test of DDDR Versus DDD Pacing. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1992, 15, 1908-1913.	1.2	38
714	Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. <i>American Journal of Cardiology</i> , 1992, 70, 69-72.	1.6	239
715	Flecainide: evidence of non-linear kinetics. <i>European Journal of Clinical Pharmacology</i> , 1991, 41, 57-59.	1.9	18
716	Usefulness of nicorandil in congestive heart failure. <i>American Journal of Cardiology</i> , 1990, 65, 343-348.	1.6	21
717	Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy. <i>Cardiovascular Drugs and Therapy</i> , 1990, 4, 281-287.	2.6	24
718	Cost-Effectiveness of Implantable Cardioverter-Defibrillators. , 0 , 263-279.		0
719	Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10â€™220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation (EORP-AF) general long-term registry. <i>European Journal of Preventive Cardiology</i> . 0. . .	1.8	3